WO2015051341A1 - Inhibitors of erk and methods of use - Google Patents

Inhibitors of erk and methods of use Download PDF

Info

Publication number
WO2015051341A1
WO2015051341A1 PCT/US2014/059197 US2014059197W WO2015051341A1 WO 2015051341 A1 WO2015051341 A1 WO 2015051341A1 US 2014059197 W US2014059197 W US 2014059197W WO 2015051341 A1 WO2015051341 A1 WO 2015051341A1
Authority
WO
WIPO (PCT)
Prior art keywords
aryl
cycloalkyl
oheterocyclyl
alkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/059197
Other languages
English (en)
French (fr)
Inventor
Liangsheng Li
Tao Wu
Jun Feng
Pingda Ren
Yi Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Araxes Pharma LLC
Original Assignee
Araxes Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL14850964T priority Critical patent/PL3052096T3/pl
Priority to EA201690708A priority patent/EA032196B1/ru
Priority to KR1020167011270A priority patent/KR20160081908A/ko
Priority to EP14850964.9A priority patent/EP3052096B8/en
Priority to CN201480054909.3A priority patent/CN105636586B/zh
Priority to JP2016546894A priority patent/JP6427197B2/ja
Priority to US15/026,581 priority patent/US9624228B2/en
Priority to LTEP14850964.9T priority patent/LT3052096T/lt
Priority to AU2014331628A priority patent/AU2014331628B2/en
Priority to MEP-2018-90A priority patent/ME02991B/me
Priority to DK14850964.9T priority patent/DK3052096T3/en
Priority to ES14850964.9T priority patent/ES2664794T3/es
Priority to SI201430659T priority patent/SI3052096T1/en
Priority to EP17204999.1A priority patent/EP3363800A1/en
Priority to SG11201602572YA priority patent/SG11201602572YA/en
Priority to HRP20180538TT priority patent/HRP20180538T1/hr
Priority to BR112016006994A priority patent/BR112016006994A8/pt
Priority to SM20180205T priority patent/SMT201800205T1/it
Application filed by Araxes Pharma LLC filed Critical Araxes Pharma LLC
Priority to RS20180373A priority patent/RS57058B1/sr
Priority to CA2924584A priority patent/CA2924584A1/en
Priority to MX2016004163A priority patent/MX2016004163A/es
Publication of WO2015051341A1 publication Critical patent/WO2015051341A1/en
Priority to PH12016500432A priority patent/PH12016500432A1/en
Priority to IL244488A priority patent/IL244488A0/en
Priority to ZA2016/01701A priority patent/ZA201601701B/en
Anticipated expiration legal-status Critical
Priority to US15/439,719 priority patent/US9951078B2/en
Priority to US15/896,929 priority patent/US10301317B2/en
Priority to CY20181100340T priority patent/CY1120095T1/el
Priority to AU2018250439A priority patent/AU2018250439A1/en
Priority to US16/370,718 priority patent/US20190292194A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • ERK kinases are serine/threonine kinases that mediate intracellular signal transduction pathways involved in tumor growth, progression and metastasis. ERK is involved in the Ras/Raf/MEK/ERK pathway, which plays a central role in regulating cellular processes by relaying extracellular signals from ligand-bound cell surface receptor tyrosine kinases (RTKs) such as ErbB (e.g. EGFR, Her-2, etc), VEGF, PDGF, and FGF receptor tyrosine kinases.
  • RTKs ligand-bound cell surface receptor tyrosine kinases
  • ErbB e.g. EGFR, Her-2, etc
  • VEGF vascular endothelial growth factor
  • PDGF vascular endothelial growth factor
  • FGF receptor tyrosine kinases Activation of an RTK triggers a series of phosphorylation events, beginning with the activation of Ras, followed by
  • Raf MAP kinase kinase 1/2
  • ERK 1/2 MAP kinase kinase 1/2
  • ERK phosphorylation by MEK occurs on Y204 and T202 for ERK1 and Y185 and T183 for ERK2 (Ahn et al., Methods in Enzymology 2001, 332, 417-431).
  • Phosphorylated ERK dimerizes and translocates to and accumulates in the nucleus (Khokhlatchev et al., Cell 1998, 93, 605-615).
  • ERK is involved in several important cellular functions, including but not limited to nuclear transport, signal transduction, DNA repair, nucleosome assembly and translocation, and mRNA processing and translation (Ahn et al., Molecular Cell 2000, 6, 1343-1354).
  • ERK2 phosphorylates a multitude of regulatory proteins, including the protein kinases Rsk90 and MAPKAP2 ((Bjorbaek et al., 1995, . Biol. Chem. 270, 18848; Rouse et al., 1994, Cell 78, 1027), and transcription factors such as ATF2, Elk-1, c-Fos, and c-Myc (Raingeaud et al., 1996, Mol .
  • bRaf mutations have been identified in more than malignant melanomas (60%), thyroid cancers (greater than 40%) and colorectal cancers. These mutations in bRaf result in a constitutively active Ras/Raf/MEK/ERK kinase cascade. Studies of primary tumor samples and cell lines have also shown constitutive or overactivation of the Ras/Raf/MEK/ERK kinase pathway in cancers of pancreas, colon, lung, ovary and kidney (Hoshino, R. et al., Oncogene 1999, 18, 813-822).
  • ERK2 has been shown to play a role in the negative growth control of breast cancer cells (Frey and Mulder, 1997, Cancer Res. 57, 628) and hyperexpression of ERK2 in human breast cancer has been reported (Sivaraman et al., 1997, J Clin. Invest. 99, 1478).
  • Activated ERK2 has also been implicated in the proliferation of endothelin-stimulated airway smooth muscle cells, suggesting a role for this kinase in asthma (Whelchel et al., 1997, Am. J. Respir. Cell Mol. Biol. 16, 589).
  • upstream e.g. Ras, Raf
  • downstream e.g. ATF2, c-Fos, c-Myc
  • the invention provides a compound of Formula I:
  • Y is CR 5 ;
  • X 6 is N or C
  • X 7 is O, N, NR 72 or CR 71 ;
  • X 8 is O, N, NR 82 or CR 81 ;
  • X 10 is O, N, NR 92 or CR 91 ;
  • Ri is -Ci.ioalkyl, -C 2 -ioalkenyl, -C 2 -ioalkynyl, -C M oheteroalkyl, -C 3 _ 10 aryl, -Ci.i 0 hetaryl, -C 3 .
  • oheterocyclyl-C M ohetaryl or -C M oheterocyclyl-C 3 _ 10 cycloarkyl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • Ri ' is hydrogen, -C 1-10 alkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C ⁇ 10 hetaryl, -C 3 _ 10 cycloalkyl, -C M oheterocyclyl, -C M oalkyl-C 3 _ 10 aryl, -C M oalkyl-C M ohetaryl, -C M oalkyl- C 3 . 10 cycloalkyl, -C M oalkyl-C M oheterocyclyl, -C 2 .
  • oheterocyclyl-C M oalkyl -L-C M oheterocyclyl-C ⁇ oalkenyl, -L-C 1 . 10 heterocyclyl-C 2 . 10 alkynyl, -L-C ⁇ 10 heterocyclyl-C 3 . 10 aryl, -L-C M oheterocyclyl-C M ohetaryl, or -L-C M oheterocyclyl-C ⁇ ocycloalkyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents;
  • R 6 is hydrogen, -Ci_i 0 alkyl, -C 2 _i 0 alkenyl, -C 2 _i 0 alkynyl, -Ci_i 0 heteroalkyl, -C 3 _i 0 aryl, -Ci_ 10 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 aikyl-C 3 -i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci_i 0 alkyl- C 3 _iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 2 .i 0 alkenyl-C 3 .i 0 aryl, -C 2 .i 0 alkenyl-C 3 .i
  • each of R 10 and R 14 is independently -Cm alkyl, -C 2 -ioalkenyl, -C2-10 alkynyl, -Ci_i 0 heteroalkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, optionally substituted by one or more independent R n substituents;
  • each of R u , R 12 Ri 3 and R 15 is independently hydrogen, halogen, -Cn 0 alkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen, halogen, -Cn 0 alkyl, -C 2 . 10 alkenyl, -C 2 _ 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 . 10 cycloalkyl, -C M0 heterocyclyl, or wherein R 31 together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S;
  • ring A comprises at least two heteroatoms selected from N, O, or S;
  • the invention provides a compound of Formula I- A:
  • the invention provides a compound of Formula I-B: or a pharmaceutically acceptable salt or prodrug thereof.
  • the invention provides a compound of Formula II: or a pharmaceutically acceptable salt or prodrug thereof.
  • X 2 is NRi.
  • X 5 is N and X 6 is C.
  • X 5 is C and X 6 is C.
  • X 9 is CR 2 i .
  • the invention provides a compound of Formula II-A:
  • the invention provides a compound of Formula II-D:
  • the invention provides a compound of Formula II-G:
  • R 21 is selected from the group consisting of -L-Ci_i 0 heteroalkyl, -L-C 3 _ioaryl, -L-Ci_i 0 hetaryl, -L-C 3 .
  • R 10 cycloalkyl, and -L-Ci_i 0 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents; and L is bond.
  • R 2 i is -L-Ci_i 0 hetaryl unsubstituted or substituted by one or more independent R 12 substituents; and L is bond.
  • the Ci_ 10 hetaryl of R 21 comprises one or more nitrogen atoms.
  • the Ci_i 0 hetaryl of R 21 is selected from the group consisting of pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, and pyridazinyl. In some embodiments, the Ci_i 0 hetaryl of R 21 is unsubstituted. In other embodiments, the Ci_i 0 hetaryl or R 21 is substituted with one, two, or three independent R 12 substituents. In some embodiments, each R 12 substituent is independently selected from the group consisting of -Cm alkyl, -C 2 . 10 alkenyl, -C 2 .
  • each R 12 substituent is independently selected from the group consisting -Me, -Et, -i-Pr, -n-Pr, OH, -OMe, - OEt, -OPr.
  • Formula I including I-A and I-B
  • Formula II including Formula IF , II-A, II-B, II-C, II-D, II-E, II-F and II-G
  • Formula III including Formula III-A and III-B
  • Formula IV including IV-A, IV-B, IV-C and IV-D
  • Formula V including V-A, V-B, V-C and V-D
  • R l is -Q.
  • Ri is -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -Ci_ 10 alkyl-C 3 -i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci_i 0 alkyl -Ci_i 0 hetaryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or - Ci-ioheterocyclyl-C 3 _ioaryl, unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • Ri is -Ci.ioalkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.iohetaryl, -Ci_ 10 heterocyclyl-Ci-ioalkyl, or -Ci.ioheterocyclyl-C 3 .i 0 aryl, unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • Ri is -Ci.ioalkyl-C 3 .i 0 aryl or -Ci_ 10 heterocyc one or more independent R 10 or R u substituents.
  • RI is R x is -C M oheterocyclyl, ! oheterocyclyl-C M oalkyl, or -C M oheterocyclyl-C ⁇ oaryl, unsubstituted or substituted by one or independent R 10 or R u substituents.
  • R x is , unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • Formula I including I- A and I-B
  • Formula II including Formula IF , II-A, II-B, II-C, II-D, II-E, II-F and II-G
  • Formula III including Formula III-A and III-B
  • Formula IV including IV-A, IV-B, IV-C and IV-D
  • Formula V including V-A, V-B, V-C and V-D
  • R 72 is H.
  • the invention provides a compound of Formula III:
  • X 2 is NRi.
  • X 5 is N and X 6 is C.
  • X 5 is C and X 6 is C.
  • X 8 is N and X 10 is N.
  • X 9 is CR 2 i .
  • the invention provides a compound of Formula III-A:
  • the invention provides a compound of Formula III-B:
  • the invention provides a compound of Formula IV-A:
  • X 2 is NRi.
  • X 5 is N and X 6 is C.
  • X 5 is C and X 6 is C.
  • X 8 is N.
  • X 9 is CR 2 i .
  • the invention provides a compound of Formula IV-B:
  • the invention provides a compound of Formula IV-D:
  • the invention provides a compound of Formula V-A:
  • X 2 is CRiRi ' .
  • X5 is N and X 6 is C.
  • X 5 is C and X 6 is C.
  • X 8 is N.
  • X 9 is CR 2 i.
  • the inventio a compound of Formula IV-B:
  • the invention provides a compound of Formula IV -C:
  • the invention provides a compound of Formula IV-D: or a pharmaceutically acceptable salt or prodrug thereof.
  • Formula I including I- A and I-B
  • Formula II including Formula IF , II-A, II-B, II-CII-D, II-E and II-F
  • Formula III including Formula III-A and III-B
  • Formula IV including IV-A, IV-B, IV-C and IV-D
  • Formula V including V-A, V-B, V-C and V-D
  • R 5 is hydrogen
  • Formula I including I- A and I-B
  • Formula II including Formula IF , II-A, II-B, II-CII-D, II-E and II-F
  • Formula III including Formula III-A and III-B
  • Formula IV including IV-A, IV-B, IV-C and IV-D
  • Formula V including V-A, V-B, V-C and V-D
  • X 4 is CR 4.
  • X 4 is CR 4 and R 4 is H.
  • X 4 is N.
  • Formula I including I- A and I-B
  • Formula II including Formula IF , II-A, II-B, II-C, II-D, II-E, II-F and II-G
  • Formula III including Formula III-A and III-B
  • Formula IV including IV-A, IV-B, IV-C and IV-D
  • Formula V including V-A, V-B, V-C and V-D
  • X 9 is CR 2 i or NR 2 2 and R 2 i or R 22 is halogen, -CN, -L-C 3 _ioaryl, -L-Ci_i 0 hetaryl, -L-C 3 _iocycloalkyl, or -L-Ci_ 10 heterocyclyl, unsubstituted or substituted by one or more independent R 12 substituents.
  • Formula I including I- A and I-B
  • Formula II including Formula IF , II-A, II-B, II-C, II-D, II-E, II-F and II-G
  • Formula III including Formula III-A and III-B
  • Formula IV including IV-A, IV-B, IV-C and IV-D
  • Formula V including V-A, V-B, V-C and V-D
  • X 9 is CR 21 and R 21 is halogen or -CN.
  • X 9 is CR 2 i and R 21 is -L-C 3 -i 0 aryl, -L-Ci_i 0 hetaryl, - L-C 3 .
  • X 9 is CR 21 and R 2 is -L-C M ohetaryl or -L-C 3 . 10 heterocyclyl, unsubstituted or substituted by one or more independent R 12 substituents.
  • the invention provides a method of inhibiting activity of a protein kinase present in a cell, comprising contacting said cell with an effective amount of a compound, pharmaceutically acceptable salt, or prodrug disclosed herein.
  • the protein kinase is ERK.
  • the compound inhibits ERK at an IC50 value of less than about 1000 nM. In other embodiments, the compound inhibits ERK at an IC50 value of less than about 100 nM. In further embodiments, the compound inhibits ERK at an IC50 value of less than about 10 nM.
  • the contacting step takes place in vitro. In other embodiments, the contacting step takes place in vivo.
  • the invention provides a method of ameliorating a disorder comprising administering to a subject in need thereof an effective amount of a compound, pharmaceutically acceptable salt, or prodrug of a compound of any of the preceding claims, wherein the disorder is selected from the group consisting of cancer, bone disorder, inflammatory disease, immune disease, nervous system disease, metabolic disease, respiratory disease, and cardiac disease.
  • the disorder is cancer selected from the group consisting of breast cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), thyroid cancer, seminomas, melanoma, bladder cancer, liver cancer, kidney cancer, myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML), and colorectal cancer.
  • the cancer is melanoma or colorectal cancer.
  • the disorder is mediated by ERK 1 and/or ERK2.
  • the method further comprises administering another anti-cancer agent.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the compound disclosed herein and a pharmaceutically acceptable excipient.
  • the compound is present in a therapeutically effective amount.
  • the composition is formulated in an oral dosage.
  • the composition is formulated as a tablet or a capsule.
  • Figure 1 shows the biological data from the ERK kinase inhibition, p90RSK ELISA, and cellular proliferation assays for compounds provided by the invention wherein, the following symbols are used: + (greater than ⁇ ), ++ (250nM to 1000 nM), +++ (50 nM to 250 nM), and ++++ (less than 50 nM).
  • the term "effective amount” or “therapeutically effective amount” refers to that amount of a compound described herein that is sufficient to effect the intended application including but not limited to disease treatment, as defined below.
  • the therapeutically effective amount may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • the term also applies to a dose that will induce a particular response in target cells, e.g. reduction of platelet adhesion and/or cell migration.
  • the specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
  • treatment or “treating,” or “palliating” or “ameliorating” is used interchangeably. These terms refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and/or a prophylactic benefit.
  • therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
  • a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the subject, notwithstanding that the subject may still be afflicted with the underlying disorder.
  • the compositions may be administered to a subject at risk of developing a particular disease, or to a subject reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
  • a prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
  • co-administration encompass administration of two or more agents to an animal so that both agents and/or their metabolites are present in the subject at the same time.
  • Co-administration includes simultaneous administration in separate compositions, administration at different times in separate compositions, or administration in a composition in which both agents are present.
  • pharmaceutically acceptable salt refers to salts derived from a variety of organic and inorganic counter ions well known in the art and include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like, when the molecule contains an acidic functionality; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate (methane sulfonate), ethane sulfonate, acetate, maleate, oxalate, phosphate, and the like.
  • organic or inorganic acids such as hydrochloride, hydrobromide, tartrate, mesylate (methane sulfonate), ethane sulfonate, acetate, maleate, oxalate, phosphate, and the like.
  • more than one of the basic moieties may be converted to the salt form, including but not limited to a bis- or tris- salt.
  • a compound having more than one basic moiety may form a salt at only one of the basic moieties.
  • antagonists are used interchangeably, and they refer to a compound having the ability to inhibit a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the terms “antagonist” and “inhibitors” are defined in the context of the biological role of the target protein. While preferred antagonists herein specifically interact with (e.g. bind to) the target, compounds that inhibit a biological activity of the target protein by interacting with other members of the signal transduction pathway of which the target protein is a member are also specifically included within this definition. A preferred biological activity inhibited by an antagonist is associated with the development, growth, or spread of a tumor.
  • agonist refers to a compound having the ability to initiate or enhance a biological function of a target protein, whether by inhibiting the activity or expression of the target protein. Accordingly, the term “agonist” is defined in the context of the biological role of the target polypeptide. While preferred agonists herein specifically interact with (e.g. bind to) the target, compounds that initiate or enhance a biological activity of the target polypeptide by interacting with other members of the signal transduction pathway of which the target polypeptide is a member are also specifically included within this definition.
  • agent refers to a biological, pharmaceutical, or chemical compound or other moiety.
  • Non-limiting examples include a simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, antibody fragment, a vitamin derivative, a carbohydrate, a toxin, or a chemotherapeutic compound.
  • Various compounds can be synthesized, for example, small molecules and oligomers (e.g., oligopeptides and oligonucleotides), and synthetic organic compounds based on various core structures.
  • various natural sources can provide compounds for screening, such as plant or animal extracts, and the like.
  • isolated compound or “isolated agent” refers to a biological, pharmaceutical, or chemical compound or other moiety that is isolated to a purity of greater than 90%.
  • “Signal transduction” is a process during which stimulatory or inhibitory signals are transmitted into and within a cell to elicit an intracellular response.
  • a modulator of a signal transduction pathway refers to a compound which modulates the activity of one or more cellular proteins mapped to the same specific signal transduction pathway.
  • a modulator may augment (agonist) or suppress (antagonist) the activity of a signaling molecule.
  • an "anti-cancer agent”, “anti-tumor agent” or “chemotherapeutic agent” refers to any agent useful in the treatment of a neoplastic condition.
  • One class of anti-cancer agents comprises chemotherapeutic agents.
  • “Chemotherapy” means the administration of one or more chemotherapeutic drugs and/or other agents to a cancer patient by various methods, including intravenous, oral, intramuscular, intraperitoneal, intravesical, subcutaneous, transdermal, buccal, or inhalation or in the form of a suppository.
  • cell proliferation refers to a phenomenon by which the cell number has changed as a result of division. This term also encompasses cell growth by which the cell morphology has changed (e.g., increased in size) consistent with a proliferative signal.
  • selective inhibition refers to a biologically active agent refers to the agent's ability to preferentially reduce the target signaling activity as compared to off-target signaling activity, via direct or indirect interaction with the target.
  • ERK1 and/or ERK2 activity refers to the agent's ability to modulate signal transduction mediated by ERK1 and/or ERK2.
  • modulation of ERK1 and/or ERK2 activity is evidenced by alteration in signaling output from the Ras/Raf/MEK/ERK pathway.
  • Subject refers to an animal, such as a mammal, for example a human.
  • the methods described herein can be useful in both human therapaeutics and veterinary applications.
  • the subject is a mammal.
  • the subject is human.
  • Radionuclides e.g., actinium and thorium radionuclides
  • LET low linear energy transfer
  • beta emitters conversion electron emitters
  • high-energy radiation including without limitation x-rays, gamma rays, and neutrons.
  • Prodrug is meant to indicate a compound that may be converted under physiological conditions or by solvolysis to a biologically active compound described herein.
  • prodrug refers to a precursor of a biologically active compound that is pharmaceutically acceptable.
  • a prodrug may be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis.
  • the prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam).
  • prodrugs are also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of an active compound, as described herein may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound.
  • Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a mammalian subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of a hydroxy functional group, or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like.
  • in vivo refers to an event that takes place in a subject's body.
  • in vitro refers to an event that takes places outside of a subject's body.
  • an in vitro assay encompasses any assay run outside of a subject assay.
  • in vitro assays encompass cell- based assays in which cells alive or dead are employed.
  • In vitro assays also encompass a cell-free assay in which no intact cells are employed.
  • connection of compound name moieties are at the leftmost recited moiety. That is, the substituent name starts with a linking moiety, continues with any linking moieties, and ends with a terminal moiety.
  • substituent name starts with a linking moiety, continues with any linking moieties, and ends with a terminal moiety.
  • "-L-Ci.ioalkyl-C3_iocycloalkyl” has a terminal group -C 3 . 10 cycloalkyl group attached to a linking -Ci_i 0 alkyl moiety which is attached to an element L, which is itself connected to the chemical species bearing the substituent.
  • structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of carbon by 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
  • heteroatom or "ring heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
  • alkyl is used to mean an alkyl having 1-10 carbons - that is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbons in a straight or branched configuration.
  • alkyl includes both branched and straight chain alkyl groups, or a combination thereof.
  • Alkyl groups are fully saturated, unsubstituted or substituted, and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. Cno means one to ten carbons and C 2 -io means two to ten carbons).
  • Typical alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec -butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, and the like.
  • An alkyl is unsubstituted or substituted.
  • alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from two to ten carbon atoms (i.e. -C 2 -ioalkenyl). Whenever it appears herein, a numerical range such as “C 2 -io” refers to each integer in the given range; e.g., "C 2 -ioalkenyl” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms.
  • an alkenyl comprises two to eight carbon atoms (e.g., -C 2 - 8 alkenyl). In other embodiments, an alkenyl comprises two to five carbon atoms (e.g., -C 2 - 5 alkenyl).
  • the alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-l -enyl (i.e., allyl), but-l -enyl, pent-l -enyl, penta-l ,4-dienyl, and the like.
  • An alkenyl is unsubstituted or substituted.
  • alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, and having from two to ten carbon atoms (i.e. -C 2 - 10 alkynyl). Whenever it appears herein, a numerical range such as “C 2 - 10 " refers to each integer in the given range; e.g., "C 2 -i 0 alkynyl” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms.
  • an alkynyl comprises two to eight carbon atoms (e.g., -C 2 - 8 alkynyl). In other embodiments, an alkynyl has two to five carbon atoms (e.g., -C 2 - 5 alkynyl).
  • the alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. An alkynyl is unsubstituted or substituted.
  • heteroalkyl refers to a straight or branched chain radical group, consisting of at least one carbon atoms and at least one heteroatom selected from the group consisting of O, N, P, Si and S, and wherein the nitrogen, phosphorus, and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) O, N, P and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which alkyl group is attached to the remainder of the molecule.
  • the alkyl portion of the moiety is unsubstituted or substituted.
  • heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
  • heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxo, alkylenedioxo, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(0)OR'- represents both - C(0)OR'- and -R'OC(O)-.
  • heteroalkyl groups include those groups that are attached to the remainder of the molecule through a heteroatom, such as -C(0)R', -C(0)NR', - NR'R , -OR', -SR , and/or -S0 2 R'.
  • heteroalkyl is recited, followed by recitations of specific heteroalkyl groups, such as -NR'R” or the like, it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as -NR'R” or the like.
  • aromatic refers to an aromatic radical with three to sixteen carbon atoms (e.g., -C 3 - 16 aromatic or -C 3 - 16 aryl) which has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl).
  • a numerical range such as “C 3 - 10 " refers to each integer in the given range; e.g., "-C 3 - 10 aryl” means that the aryl group may consist of 3 ring atoms, 4 ring atoms, etc., up to and including 10 ring atoms.
  • aryl includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups.
  • aryl include, but are not limited to, phenyl, 4-chlorophenyl, 4-fluorophenyl, 4-bromophenyl, 3-nitrophenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methyphenyl, 4-methylphenyl, 4-ethylphenyl, 2- methyl-3-methoxyphenyl, 2,4-dibromophenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl, 2,4,6- trichlorophenyl, 4-methoxyphenyl, naphthyl, 2-chloronaphthyl, 2,4-dimethoxynaphthyl, 4- (trifluoromethyl)naphthyl, 2-iodo-4-methylnaphthyl, and the like.
  • heteroaryl or, alternatively, “heteroaromatic”, “hetaryl”, 'heteroar” or “hetar” refers to an aromatic radical with one to sixteen carbon atoms (e.g., -Cneheteroaryl) that further includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur, and which may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system. Whenever it appears herein, a numerical range such as "C !
  • o refers to each integer in the given range; e.g., "-Ci-iohetaryl” means that the heteroaryl group may consist of 1 carbon atoms, 2 carbon atoms, etc., up to and including 10 carbon atoms.
  • An "N-containing heteroaromatic” or “N-containing heteroaryl” moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom.
  • the polycyclic heteroaryl group may be fused or non- fused.
  • the heteroatom(s) in the heteroaryl radical is optionally oxidized.
  • One or more nitrogen atoms, if present, are optionally quaternized.
  • heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
  • heteroaryl include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[ ][l,4]dioxepinyl, benzo[b][l,4]oxazinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzofurazanyl, benzothiazolyl, benzothieny
  • cycloalkyl refers to a saturated or partially unsaturated ring structure with three to ten carbon atoms (i.e. -C 3 _iocycloalkyl). Whenever it appears herein, a numerical range such as “C 3 _io” refers to each integer in the given range; e.g., "-C 3 .iocycloalkyl” means that the cycloalkyl group may consist of 3 carbon atoms, 4 carbon atoms, etc., up to and including 10 carbon atoms.
  • the term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. A cycloalkyl moiety is unsubstituted or substituted.
  • heterocyclyl refers to a 3-, 4-, 5-, or 6-membered saturated or partially unsaturated ring containing one, two, or three heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen and sulfur; or to a bicyclic ring system containing up to 10 atoms including at least one heteroatom independently selected from oxygen, nitrogen, and sulfur wherein the ring containing the heteroatom is saturated.
  • CMO refers to each integer in the given range; e.g., "-C M oheterocyclyl” means that the heterocycloalkyl group may consist of 1 carbon atoms, 2 carbon atoms, etc., up to and including 10 carbon atoms.
  • heterocyclyl include, but are not limited to, tetrahydrofuranyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, 4-pyranyl, tetrahydropyranyl, thiolanyl, morpholinyl, piperazinyl, dioxolanyl, dioxanyl, indolinyl, and chromanyl.
  • a hetereocycloalkyl moiety is unsubstituted or substituted.
  • -Ci-ioalkyl-C 3 .ioaryl refers to an aryl group, which contains 3 to 10 carbons, attached to a linking alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, such as for example, 1-phenylethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-i 0 alkyl-Ci.iohetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, such as for example, 2-pyrimidinylethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioalkyl-C 3 -iocycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking alkyl group, branched or straight chain and containing 1 to 10 carbon atoms such as for example, 2-cyclopropylethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C M oalkyl-C ⁇ oheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons, attached to a linking alkyl group, branched or straight chain and containing 1 to 10 carbon atoms such as for example, 4-piperidinyleth-l -yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl refers to an aryl group, which contains 3 to 10 carbons, attached to a linking alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms, such as for example, 1 -phenyl vinyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 2 -ioalkenyl-Ci.iohetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms, such as for example, 2-pyrimidinylvinyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C2-ioalkenyl-C 3 -iocycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms such as for example, 2-cyclopropylvinyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 2 -ioalkenyl-Ci.ioheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons, attached to a linking alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms such as for example, 4-piperidinylethen-l -yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 2 -ioalkynyl-C 3 . 10 aryl refers to an aryl group, which contains 3 to 10 carbons, attached to a linking alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms, such as for example, 1-phenylethynyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 2 -ioalkynyl-C 1 . 10 hetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms, such as for example, 2-pyrimidinylethynyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 2 -ioalkynyl-C 3 -iocycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms such as for example, 2-cyclopropylethynyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 2 -ioalkynyl-Ci.ioheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons, attached to a linking alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms such as for example, 4-piperidethyn-l-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioheteroalkyl-Cs.ioaryl refers to an aryl group, which contains 3 to 10 carbons, attached to a linking heteroalkyl group, branched or straight chain and containing 1 to 10 carbon atoms and at least one heteroatom, such as for example, 1-phenylethoxy ethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioheteroalkyl-C M ohetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking heteroalkyl group, branched or straight chain and containing 1 to 10 carbon atoms and at least 1 heteroatom, such as for example, 2- pyrimidinylethoxyethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Cnoheteroalkyl-Cs-iocycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking heteroalkyl group, branched or straight chain and containing 1 to 10 carbon atoms and at least one heteroatom, such as for example, 2-cyclopropylethoxyethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioheteroalkyl-Ci-ioheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons, attached to a linking heteroalkyl group, branched or straight chain and containing 1 to 10 carbon atoms and at least one heteroatom, such as for example, 4-piperidinylethoxyeth-l-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioalkoxy-C 3 _ioaryl refers to an aryl group, which contains 3 to 10 carbons, attached to a linking oxygen atom that is further connected to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, such as for example, 1-phenoxyethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioalkoxy-C M ohetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking oxygen atom that is further connected to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, such as for example, 2-pyrimidoxyethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioalkoxy-Cs-iocycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking oxygen atom that is further connected to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms such as for example, 2-cyclopropoxyethyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioalkoxy-Ci-ioheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons, attached to a linking oxygen atom that is further connected to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms such as for example, 4-piperidoxyeth-l-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • the term refers to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, attached to a linking aryl group, which contains 3 to 10 carbons, such as for example, 4-ethylphenyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 3 _ 1 oaryl-C2-ioalkenyl refers to an alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking aryl group, which contains 3 to 10 carbons, such as for example, 4-ethenylphenyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 3 _ 1 oaryl-C 2 -ioalkynyr refers to an alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking aryl group, which contains 3 to 10 carbons, such as for example, 4-ethynylphenyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl-Ci-iohetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking aryl group, which contains 3 to 10 carbons, such as for example, 4-pyrimidinylphen-4-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 3 .i 0 aryl-C 3 -iocycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking aryl group, which contains 3 to 10 carbons, such as for example, 4- cyclopropylphenyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • aryl-Ci-ioheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking aryl group, which contains 3 to 10 carbons, such as for example, 4-piperidinylphen-4-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci.iohetaryl-Ci-i 0 alkyl refers to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, attached to a linking hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-ethylpyrimidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C ⁇ ohetaryl -C 2 -ioalkenyl refers to an alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking hetaryl group, which contains 1 to 10 and at least one heteroatom carbons, such as for example, 4-ethenylpyrimidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C ⁇ ohetaryl -C 2 -ioalkynyl refers to an alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking hetaryl group, which contains 1 to 10 and at least one heteroatom carbons, such as for example, 4-ethynylpyrimidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci_i 0 hetaryl -C 3 -i 0 aryl refers to an aryl group, which contains 1 to 10 carbons, attached to a linking hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-phenylpyrimidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci_i 0 hetaryl -C 3 - 10 cycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-cyclopropylpyrimidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C ⁇ ohetaryl -C ioheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-piperidinylpyrimidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Cs.iocycloalkyl-Ci-ioalkyl refers to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, attached to a linking cycloalkyl group, which contains 3 to 10 carbons, such as for example, 2-ethylcyclopentyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • cycloalkyl-C 2 -ioalkenyl refers to an alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking cycloalkyl group, which contains 3 to 10 carbons, such as for example, 2-ethenylcyclopentyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C 3 .iocycloalkyl-C 2 -ioalkynyl refers to an alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking cycloalkyl group, which contains 3 to 10 carbons, such as for example, 2-ethynylcyclopentyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C3.iocycloalkyl-C 3 -ioaryl refers to an aryl group, which contains 3 to 10 carbons, attached to a linking cycloalkyl group, which contains 3 to 10 carbons, such as for example, 2- phenylcyclopentyl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Cs ⁇ ocycloaikyl-Ci-iohetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking cycloalkyl group, which contains 3 to 10 carbons, such as for example, 4-pyrimidinylcyclopent-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Cs.iocycloalkyl-Ci-ioheterocyclyl refers to a heterocyclyl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking cycloalkyl group, which contains 3 to 10 carbons, such as for example, 4-piperidinylcyclopent-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci.ioheterocyclyl-Ci-i 0 alkyl refers to an alkyl group, branched or straight chain and containing 1 to 10 carbon atoms, attached to a linking heterocyclyl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-ethylpiperidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci-ioheterocyclyl-C 2 -ioalkenyl refers to an alkenyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking heterocyclyl group, which contains 1 to 10 and at least one heteroatom carbons, such as for example, 4-ethenylpiperidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -Ci.ioheterocyclyl-C 2 -ioalkynyl refers to an alkynyl group, branched or straight chain and containing 2 to 10 carbon atoms, attached to a linking heterocyclyl group, which contains 1 to 10 and at least one heteroatom carbons, such as for example, 4-ethynylpiperidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C M oheterocyclyl-Cs- ! oaryl refers to an aryl group, which contains 1 to 10 carbons, attached to a linking heterocyclyl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-phenylpiperidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • -C M oheterocyclyl-Cnohetaryl refers to a hetaryl group, which contains 1 to 10 carbons and at least one heteroatom, attached to a linking heterocyclyl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-pyrimidinylpiperidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • heterocyclyl -C 3 -iocycloalkyl refers to a cycloalkyl group, which contains 3 to 10 carbons, attached to a linking heterocyclyl group, which contains 1 to 10 carbons and at least one heteroatom, such as for example, 4-cyclopropylpiperidin-2-yl, and the like. Either portion of the moiety is unsubstituted or substituted.
  • halo or halogen refers to fluoro, chloro, bromo, or iodo.
  • haloalkyl refers to an alkyl group substituted with one or more halo groups, for example chloromethyl, 2-bromoethyl, 3-iodopropyl, trifluoromethyl, perfluoropropyl, 8-chlorononyl, and the like.
  • a haloalkyl moiety can be further substituted or not further substituted.
  • amine refers to a -NR'R" moiety, where each R is independently hydrogen, -Cnoalkyl, -C ! - 10 heteroalkyl, -Ci-iohaloalkyl, -C 3 _ 10 aryl, -Ci. 10 heteroaryl, -d- K jaikyl-C M ohetaryl, -C 3 _ 10 cycloaikyl, -C M oheterocyclyl, or -Ci-ioalkyl-C M oheterocyclyl, unless stated otherwise specifically in the specification.
  • R' and R" of a - NR'R" moiety are not hydrogen, R' and R' ' can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
  • - NR'R is meant to include, but not be limited to, 1- pyrrolidinyl and 4-morpholinyl.
  • an amino group is optionally substituted by one or more substituent which independently is: -Cnoalkyl, -Ci- 10 heteroalkyl, -C 2 -ioalkenyl, -C 2 -ioalkynyl, -Ci-i 0 heteroalkyl, -C 3 - 10 cycloalkyl, -C !
  • amide refers to a chemical moiety with formula -C(0)N(R') 2 or - NHC(0)R', where R' is selected from the group consisting of hydrogen, -Cnoalkyl, -Cnoheteroalkyl, haloalkyl, -C 3 -i 0 aryl, -Cnoalkyl-C 3 -ioaryl, -Cnohetaryl (bonded through a ring carbon), -Cn 0 alkyl-Ci- 10 hetaryl, -C 3 - 10 cycloalkyl, -Cnoalkyl-C 3 .
  • an amide is a C1-C4 radical, which includes the amide carbonyl in the total number of carbons in the radical.
  • the R' 2 of -N(R') 2 of the amide may optionally be taken together with the nitrogen to which it is attached to form a 4-, 5-, 6-, or 7- membered ring.
  • an amido group is optionally substituted independently by one or more of the substituents as described herein for alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl.
  • An amide may be an amino acid or a peptide molecule attached to a compound of Formula II or III, thereby forming a prodrug. Any amine, hydroxy, or carboxyl side chain on the compounds described herein can be amidified.
  • R group of an acyl moiety is optionally substituted by one or more substituent which independently is: -Cn 0 alkyl, -Cnoheteroalkyl, -C 2 -i 0 alkenyl, -C 2 -i 0 alkynyl, -C 3 -i 0 cycloalkyl, -Ci- 10 heterocyclyl, -C 3 - 10 aryl, -Cnoalkyl-Q.ioaryl, -Cnohetaryl, -Ci-i 0 alkyl-Ci.i 0 hetaryl, halo, -OH, -CN, - CF 3 , -OCF 3 , -N0 2 , -SiMe 3 , -OR' , -SR', -OC(0)-R ⁇ -N(R') 2 , -C(0)R', -C(0)OR
  • the R group of a carboxyl moiety is optionally substituted by one or more substituent which independently is: -Cn 0 alkyl, -Cnoheteroalkyl, -C 2 -i 0 alkenyl, -C 2 -i 0 alkynyl, -C 3 -i 0 cycloalkyl, - Ci-ioheterocyclyl, -C 3 -i 0 aryl, -Cnoalkyl-C 3 -i 0 aryl, -Cnohetaryl, -Ci-i 0 alkyl-Ci.i 0 hetaryl, halo, -OH, - CN, - CF 3 , -OCF3, -NO 2 , -SiMe 3 , -OR', -SR' , -OC(0)-R' , -N(R') 2 , -C
  • oxo refers to an oxygen atom that is double bonded to a carbon atom.
  • an "oxo” requires a second bond from the atom to which the oxo is attached. Accordingly, it is understood that oxo cannot be substituted onto an aryl or heteroaryl ring, unless it forms part of the aromatic system as a tautomer.
  • 0-2 in the context of -S(O) (0 . 2) - are integers of 0, 1, and 2.
  • the R' group of a sulfonamido moiety is optionally substituted by one or more substituent which independently is: -Cnoalkyl, -Cnoheteroalkyl, -C 2 -i 0 alkenyl, -C 2 -i 0 alkynyl, - C 3 -i 0 cycloalkyl, -Cnoheterocyclyl, -C 3 -i 0 aryl, -Cnoalkyl-C 3 -i 0 aryl, -Cnohetaryl, -Cn 0 alkyl-Ci_ !
  • Compounds described can contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention includes all such possible diastereomers as well as their racemic mixtures, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers.
  • the present invention includes all manner of rotamers and conformationally restricted states of a compound of the invention.
  • the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds.
  • the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.
  • a compound or a pharmaceutically acceptable or prodrug salt thereof is provided, wherein the compound has Formula I:
  • X 4 is N or CR 4 ;
  • X 5 is N or C;
  • X 6 is N or C;
  • X 7 is O, N, NR 72 or CR 71 ;
  • X 8 is O, N, NR 82 or CR 81 ;
  • X 9 is O, N, NR 22 or CR 21 ;
  • X 10 is O, N, NR 92 or CR 91 ;
  • Ri is-Ci_i 0 alkyl, -C 2 _ 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 _ 10 aryl, -d_ 10 hetaryl, -C 3 _ 10 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -C M oalkyl-Ci-ioheterocyclyl, -C 2 .i 0 alkenyl-C 3 .i 0 aryl, -C 2 .i 0 alkenyl-Ci 0 hetaryl, -C 2 .i 0 al
  • alkynyl-C 3 _iocycloalkyl 10 alkynyl-C 3 _iocycloalkyl, -C 2 .i 0 alkynyl-Ci.ioheterocyclyl, -Ci.ioheteroalkyl-C 3 .i 0 aryl, -Ci_i 0 heteroalkyl- Ci-iohetaryl, -Ci_ioheteroalkyl-C 3 .iocycloalkyl, -Ci-ioheteroalkyl-Ci-ioheterocyclyl, -Ci.ioalkoxy-C 3 .i 0 aryl, -C M oalkoxy-Ci-iohetaryl, -Ci.i 0 alkoxy-C 3 .iocycloalkyl, -Ci-ioalkoxy-Ci-ioheterocyclyl, -C
  • Ri' is hydrogen, -Ci_i 0 alkyl, -C 2 -ioalkenyl, -C 2 -ioalkynyl, -Ci_i 0 heteroalkyl, -C 3 .i 0 aryl, -Ci_ 10 hetaryl, -C 3 .i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci-i 0 alkyl-Ci-i 0 hetaryl, -Ci_i 0 alkyl- C 3 _iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 2 -ioalkenyl-C 3 .i 0 aryl, -C 2 -ioalkenyl-C 3 .i 0 aryl, -C 2
  • oheteroalkyl-C M ohetaryl -C M oheteroalkyl-Cs ⁇ ocycloalkyl, -C M oheteroalkyl-C M oheterocyclyl, -C ⁇ 10 alkoxy-C3.
  • ocycloalkyl -C M ohetaryl-Ci. 10 heterocyclyl, -Cs ⁇ ocycloalkyl-C M oalkyl, -Cs ⁇ ocycloaikyl-C ⁇ oaikenyl, -Cs ⁇ ocycloaikyl-C ⁇ oaikynyl, - Cs.iocycloalkyl-Cs.ioaryl, -Cs ⁇ ocycloalkyl-C M ohetaryl, -Cs ⁇ ocycloaikyl-C M oheterocyclyl, -C ⁇ !
  • oheterocyclyl-C M oalkyl -C M oheterocyclyl-C ⁇ oalkenyl, -C M oheterocyclyl-C ⁇ oalkynyl, -C ⁇ 10 heterocyclyl-C3_ioaryl, -Ci-ioheterocyclyl-Ci-iohetaryl, or -Ci.ioheterocyclyl-C 3 .iocycloalkyl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • each of R 5 , R 71 , R 81 and R 91 is independently hydrogen, halogen, -CMO alkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .
  • R 6 is hydrogen, -Ci_i 0 alkyl, -C 2 _i 0 alkenyl, -C 2 _i 0 alkynyl, -Ci_i 0 heteroalkyl, -C 3 _i 0 aryl, -Ci_ 10 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci_i 0 alkyl- C 3 _iocycloalkyl, -Ci-i 0 alkyl-Ci-i 0 heterocyclyl, -C 2 .i 0 alkenyl-C 3 .i 0 aryl, -C 2 .i 0 alkenyl-C 3 .i 0
  • alkenyl-C 3 _iocycloalkyl -C 2 .i 0 alkenyl-Ci.ioheterocyclyl, -C 2 .ioalkynyl-C 3 .i 0 aryl, -C 2 .i 0 alkynyl-Ci.
  • oheterocyclyl-C M oalkyl -C M oheterocyclyl-C 2 _ 10 arkenyl, -C M oheterocyclyl-C 2 _ 10 alkynyl, -C ⁇ 10 heterocyclyl-C3.
  • each of R 10 and R 14 is independently -CMO alkyl, -C 2 _i 0 alkenyl, -C2-10 alkynyl, -C M oheteroalkyl, -C 3 -i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -C M oheterocyclyl, optionally substituted by one or more independent R n substituents; each of R u , R 12i R13 and R 15 is independently hydrogen, halogen, -Cm alkyl, -C 2 -ioalkenyl, -C 2 .
  • each of R , R , R and R is independently hydrogen, halogen, -CMO alkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 _ 10 cycloaikyl, -C M oheterocyclyl, or wherein R 31 together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S;
  • ring A comprises at least two heteroatoms selected from N, O, or S;
  • X x is S0 2 , X 2 is NRi, and X 3 is CR 3 R 3 ' .
  • W is C, Y is CRs , X 4 is N or CR 4 , X5 is C and X 6 is C.
  • W is C, Y is CR 5i X 4 is CR 4 , X5 is N or C and X 6 is C.
  • W is C, Y is CR 5, X is CR , X5 is C and X 6 is C.
  • W is C, Y is CR 5, X is CR , X5 is N and Xe is C.
  • W is C, Y is CR 5, X is CR , X5 is C and X 6 is N.
  • X 7 is NH, X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is N and X 8 is CR 81 and X 9 is CR 21 . In some embodiments, X 7 is CR 71 , X 8 is N and X 9 is NR 22 . In some embodiments, X 7 is CR 71 , X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is O, X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is O, X 8 is CR 8 and X 9 is NR 22 .
  • X 2 is N i or CRA '
  • W is N or C
  • Y is N or CR 5
  • X 4 is N
  • C 0 or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 21 .
  • X 2 is N i or CRA '
  • X 3 is CR 3 R 3 '
  • W is C
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is NR 72 or CR 71
  • X 8 is N
  • X 9 is NR 22 or CR 21 .
  • Ri is -Ci_i 0 alkyl, -C 2 _i 0 alkenyl, -C 2 _i 0 alkynyl, -Ci_ 10 heteroalkyl, -C 3 _i 0 aryl, -C ohetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci_ 10 alkyl-Ci-i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 2 .i 0 alkenyl-C 3 .i 0 aryl, -C 2 .i 0 alkenyl-C 3 .i 0 aryl, -C 2
  • R x is -C M oalkyl, -C 3 .
  • Ri is -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -Ci_ 10 alkyl-C 3 .ioaryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -Ci_ 10 heterocyclyl-Ci-ioalkyl, or -Ci-ioheterocyclyl-C 3 -i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • Ri is -Ci_i 0 alkyl, -Ci_ 10 heterocyclyl, -Ci.ioalkyl-C 3 .i 0 aryl, -Ci.ioheterocyclyl-Ci.i 0 alkyl, or -Ci.ioheterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • R x ' is hydrogen, -Ci_i 0 alkyl, -C 2 _i 0 alkenyl, -C 2 _i 0 alkynyl, - C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 . 10 cycloalkyl, -C M oheterocyclyl, -C M oalkyl-Cs- ! oaryl, -C ⁇ !
  • R ⁇ is hydrogen, -Ci_i 0 alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _iocycloalkyl, -Ci_i 0 heterocyclyl, -C M oalkyl-Cs-ioaryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, - C3-iocycloalkyl-Ci_ioalkyl, -C 3 -iocycloalkyl-C 3 -ioaryl, -C3-iocycloalkyl-Ci_iohetaryl, -C 3 .iocycloalkyl-Ci.
  • R x ' is hydrogen, -Ci.i 0 alkyl, -Ci. 10 heterocyclyl, -C 1 . 10 alkyl-C 3 .
  • Rj ' is hydrogen, -Ci.i 0 alkyl, -Ci.i 0 heterocyclyl, -Ci.ioalkyl-C3_ 10 aryl, -C M oheterocyclyl-C M oalkyl, or - C M oheterocyclyl-Cs.ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • oheteroalkyl-Ci-iohetaryl -L -Ci.ioheteroalkyl-C 3 .i 0 cycloalkyl, -L -Ci-ioheteroalkyl-Ci-ioheterocyclyl, - L-C M oalkoxy-Q.ioaryl, -L-C M oalkoxy-C M ohetaryl, -L-C M oalkoxy-C ⁇ ocycloalkyl, -L-C M oalkoxy-Ci. 10 heterocyclyl, -L-Q.ioaryl-C M oalkyl, -L-C 3 .
  • R 21 is halogen, -CN, , -L-Ci.i 0 alkyl, -L-C 3 . 10 aryl, - L-C M ohetaryl, -L-C 3 _ 10 cycloaikyl, or -L-C M oheterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 22 is-L-Ci_i 0 alkyl, -L-C 3 _i 0 aryl, -L-Ci_i 0 hetaryl, - L-C 3 _iocycloalkyl, or -L-Ci_i 0 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 22 is-L-Ci_i 0 alkyl, -L-C 3 _i 0 aryl, -L-Ci_i 0 hetaryl, - L-C 3 _iocycloalkyl, or -L-Ci_i 0 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 3 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -Ci-ioalkyl, -C 2 _i 0 alkenyl, or -C 2 .i 0 alkynyl.
  • R 3 is hydrogen, halogen, -OH, - CF 3 , or -C oalkyl.
  • oaryl -C M oalkoxy-C M ohetaryl, -C M oalkoxy-Cs ⁇ ocycloalkyl, -C ⁇ ! oalkoxy-C M oheterocyclyl, -C 3 . 10 aryl-Ci.ioalkyl, -C 3 . 10 aryl-C 2 . 10 alkenyl, -C 3 . 10 aryl-C 2 . 10 alkynyl, -C 3 . 10 aryl-C 3 . 10 hetaryl, -C 3 . 10 aryl-C 3 .i cycloalkyl, -C 3 .
  • R 3 ' is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M oalkyl, -C 2 _ 10 aikenyl, or -C 2 . 10 alkynyl.
  • R 3 ' is hydrogen, halogen, -OH, - CF 3 , or -C M oalkyl.
  • oalkoxy-C M oheterocyclyl -Q.ioaryl-C M oalkyl, -C 3 . 10 aryl-C 2 . 10 alkenyl, -C 3 . 10 aryl-C 2 . 10 alkynyl, -C 3 . 10 aryl-C 3 . 10 hetaryl, -C 3 . 10 aryl-C 3 . 10 cycloalkyl, -Q.ioaryl-C M oheterocyclyl, -C M ohetaryl-C M oalkyl, -C ⁇ 10 hetaryl-C 2 .
  • R 4 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , -N0 2 , -CN, -S(O) 0 - 2 R 31 , -Ci-ioalkyl, -C 2 _i 0 alkenyl, or -C 2 .i 0 alkynyl.
  • R 4 is hydrogen, halogen, -OH, - CF 3 , or -Ci-ioalkyl.
  • R5 is hydrogen, halogen, Ci_io alkyl,— C 2 _ioalkenyl,— C 2 _io alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .
  • R 5 is hydrogen, halogen, or -C MO alkyl. In some embodiments, R 5 is hydrogen.
  • R 6 is -Ci_i 0 alkyl, -C 2 _i 0 alkenyl, -C 2 _i 0 alkynyl, -Ci_ 10 heteroalkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci_ 10 alkyl-Ci-iohetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 2 -ioalkenyl-C 3 .i 0 aryl, -C 2 .ioalkenyl-C 3 .i 0 aryl, -C 2 .
  • R 6 is -C M oalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 _ 10 cycloalkyl, -C M oheterocyclyl, -C M oalkyl- C 3 .
  • R 6 is -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -Ci_ 10 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -Ci_ 10 heterocyclyl-Ci-ioalkyl, or -Ci-ioheterocyclyl-C 3 -i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • R 6 is -Ci_i 0 alkyl, -Ci_ 10 heterocyclyl, -Ci.ioalkyl-C 3 .i 0 aryl, -Ci.ioheterocyclyl-Ci.i 0 alkyl, or -Ci.ioheterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • each of R 71 R 81 and R 91 is independently hydrogen, halogen, -C MO alkyl, -C 2 . 10 alkenyl, -C 2 _ 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .
  • each of R 71i R 81 and R 91 is independently hydrogen, halogen, or -C O alkyl.
  • each of R 71i R 81 and R 91 is independently hydrogen.
  • each of R 72 , R 82 and R 92 is independently hydrogen, -C MO alkyl, -C 3 _i 0 aryl, - C 3 .
  • each of R 72 , R 82 and R 92 is independently hydrogen or -C M oalkyl. In some embodiments, each of R 72 , R 82 and R 92 is independently hydrogen.
  • each of R 10 and R 14 is independently -C MO alkyl, -C 2 _ 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 . 10 cycloalkyl, -CM 0 heterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R 10 and R 14 is independently -C MO alkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .
  • each of R 10 and R 14 is independently -C MO alkyl, -C 3 . 10 aryl, -C M ohetaryl, or -CM 0 heterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R u , R 12i R 13 and R 15 is independently hydrogen, halogen, -C O alkyl, -C 2 _i 0 alkenyl, -C2-10 alkynyl, -Ci-i 0 heteroalkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 .
  • each of R u , R 12, R 13 and R 15 is independently hydrogen, halogen, -C MO alkyl, -OH, -CF 3 , -OR 3 , -NR 31 R 32 , -N0 2 , -CN, or - S(0)o- 2 R 31 .
  • each of Ru, Ri3 ⁇ 4 Ri 3 and R15 is independently hydrogen, halogen, C MO alkyl, -OH or -CF 3 .
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen, halogen, -C M0 alkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -C M0 heteroalkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 _ 10 cycloalkyl, -C M oheterocyclyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen, -C MO alkyl, -C 3 _i 0 aryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen, -C MO alkyl, -C 3 _i 0 aryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • R 31 , R 32 , R 3"3 and R 3 ⁇ 4 is independently hydro gen or -Ci-i 0 alkyl, or wherein R 31 together with R 32 form a 31 32 33 34
  • each of R , R , R and R is independently hydrogen or -Ci_ l oalkyl.
  • X 2 is NRi or CRiRi '
  • W is C
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 2 i
  • X 10 is N or CR 91 ;
  • Ri is -Ci-ioalkyl, -C 3 .i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 alkyl-C 3 . 10 aryl, -C M oalkyl-C M ohetaryl, -C M oalkyl-C ⁇ ocycloalkyl, -C M oalkyl-C M oheterocyclyl, -C 3 . 10 cycloalkyl- Ci.io lkyl, -C 3 . 10 cycloalkyl-C 3 .
  • Ri ' is hydrogen, -Ci_i 0 alkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci_ i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 3 .
  • R6 is -Ci_i 0 alkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 alkyl-C 3 .
  • each of R 10 and R 14 is independently -CMO alkyl, -C 2 -ioalkenyl, -C 2 -io alkynyl, - C M oheteroalkyl, -C 3 . 10 aryl, -C ! . 10 hetaryl, -C 3 . 10 cycloalkyl, or -C M oheterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R , R and R is independently hydrogen, -CMO alkyl, -C 3 . 10 aryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • X 2 is N i or CR1R1 '
  • X 3 is CR 3 R 3 '
  • W is C
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is NR 72 or CR 71
  • X 8 is N
  • X 9 is NR 21 or CR 21
  • X 10 is N or CR 91 ;
  • Ri is -Ci-ioalkyl, -Ci-i 0 heterocyclyl, -C M0 alkyl-C 3 .ioaryl, -C M0 alkyl-C M0 hetaryl, -C M0 alkyl-C 3 . 10 cycloalkyl, -C M0 alkyl-C M oheterocyclyl, -Ci-ioheterocyclyl-Ci-ioalkyl, or -C M oheterocyclyl-C 3 .ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • Ri ' is hydrogen -Ci-ioalkyl, -Ci-i 0 heterocyclyl, -C M0 alkyl-C 3 .ioaryl, -C M0 alkyl-C M0 hetaryl, -Ci_ 10 alkyl-C 3 _iocycloalkyl, -Ci-ioalkyl-Ci-ioheterocyclyl, -C M oheterocyclyl-Ci-i 0 alkyl, or -C M oheterocyclyl- C 3 _ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • R6 is -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -C M oalkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-i 0 alkyl-C 3 .
  • each of R 10 and R 14 independently -CMO alkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 . 10 cycloalkyl, or -C ⁇ 10 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R , R and R is independently hydrogen or -CMO alkyl, or wherein R together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • Ri is -Ci-ioalkyl, -Ci-i 0 heterocyclyl, -C M0 alkyl-C 3 .i 0 aryl, -C M0 heterocyclyl-C M0 alkyl, or -Ci_ 10 heterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or Ru substituents;
  • R 5 is hydrogen, halogen, or -C O alkyl
  • R 6 is -C M oalkyl, -C M0 heterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 heterocyclyl-C M0 alkyl, or -C ⁇ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -CM 0 alkyl, -C 3 . 10 aryl, -C M0 hetaryl, or -C M0 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u , R 12 and R 15 is independently hydrogen, halogen, -CMO alkyl, -OH, -CF 3 , -OR 3 , - NR 31 R 32 , -N0 2 , -CN, or -S(O) 0 - 2 R 31 ; each of R 31 , R 32 and R 34 is independently hydrogen or -C MO alkyl, or wherein R 31 together with R 32 form a heterocyclic ring; and
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • Ri is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or -Ci_ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • R 2 i is halogen, -CN, , -L-C oalkyl, -L-C 3 _ 10 aryl, -L-Ci_i 0 hetaryl, -L-C 3 _ 10 cycloaikyl, or -L-Ci. 10 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents;
  • each of R 3 R 3 ' and R 4 is independently hydrogen, halogen, -OH, -CF 3 , or -Ci.i 0 alkyl; or R 3 ' is -OR 6 or -NR 6 R 34 , wherein R 6 together with R 34 can optionally form a heterocyclic ring;
  • R 5 is hydrogen
  • R6 is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or -Ci_ 10 heterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -C MO alkyl, -C 3 _i 0 aryl, -Ci-iohetaryl, or -Ci-ioheterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u , R 12 and R 15 is independently hydrogen, halogen, -C MO alkyl, -OH or -CF 3 ;
  • each of R 31 and R 34 is independently hydrogen or -C MO alkyl
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • the invention also provides a compound as defined above, wherein the compound is of Formula I-A:
  • X x is S0 2 , X 2 is NR 1; and X 3 is CR 3 R 3 ' .
  • X 4 is N or CR 4 , X5 is C and X 6 is C. In some embodiments, X 4 is CR 4 , X5 is N or C and X 6 is C. In some embodiments, Y is CRs , X is CR , X5 is C and X 6 is C. In some embodiments, X 4 is CR , X5 is N and X 6 is C. In some embodiments, X 4 is CR , X5 is C and X 6 is N.
  • X 7 is NH, X 8 is N and X 9 is CR 2 i. In some embodiments, X 7 is N and X 8 is CR 8 i and X 9 is CR 2 i. In some embodiments, X 7 is CR 71 , X 8 is N and X 9 is NR 22 . In some embodiments, X 7 is CR 71 , X 8 is N and X 9 is CR 2 i. In some embodiments, X 7 is O, X 8 is N and X 9 is CR 2 i. In some embodiments, X 7 is O, X 8 is CR 8 and X 9 is NR 22 .
  • X 2 is NR X or CRA '
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 21 .
  • Ri is -Ci_i 0 aikyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -Ci_ 10 heteroalkyl, -C 3 . 10 aryl, -Ci.i 0 hetaryl, -C 3 .
  • Ri is -Ci.io lkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloaikyl, -Ci_i 0 heterocyclyl, -Ci_i 0 alkyl- C 3 _i 0 aryl, -Ci_i 0 alkyl-Ci_i 0 hetaryl, -Ci_i 0 aikyl-C 3 _iocycloalkyl, -Ci_i 0 alkyl-Ci_ioheterocyclyl, -C 3 .
  • Ri is -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -Ci_ i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci-i 0 aikyl-Ci-i 0 heterocyclyl, -Ci_ l oheterocyclyl-Ci-ioalkyl, or -Ci.ioheterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R i0 or Ru substituents.
  • Ri is -Ci_i 0 alkyl, -Ci_ 10 heterocyclyl, -Ci-ioalkyl-C 3 -i 0 aryl, -Ci-ioheterocyclyl-Ci-ioalkyl, or -Ci.ioheterocyclyl-C3_ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • R ⁇ is hydrogen, -Ci_i 0 alkyl, -C 2 -ioalkenyl, -C 2 -i 0 alkynyl, -Ci-ioheteroalkyl, -C 3 .i 0 aryl, -Ci_i 0 hetaryl, -C 3 .i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 aikyl-C 3 -i 0 aryl, -Ci_ 10 alkyl-Ci-i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 2 -ioalkenyl-C 3 .i 0 aryl, -C 2 .ioalkenyl-C 3 .i 0 ary
  • R x ' is hydrogen, -Ci_i 0 alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _iocycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 alkyl-C 3 -i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, - C 3 -iocycloaikyl-Ci-ioaikyl, -C3.iocycloalkyl-C 3 .ioaryl, -C3-iocycloalkyl-Ci_iohetaryl, -C 3 .iocycloalkyl-Ci
  • R ⁇ is hydrogen, -Ci_i 0 alkyl, -Ci_ 10 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci.i 0 alkyl-Ci_ 10 heterocyclyl, -C M oheterocyclyl-C M oalkyl, or -C M oheterocyclyl-Q.ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • Rj' is hydrogen, -C M oalkyl, -C M oheterocyclyl, -C M oalkyl-C ⁇ oaryl, -C M oheterocyclyl-C M oalkyl, or - C M oheterocyclyl-Cs.ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • R 21 is halogen, -CN, , -L-Ci_i 0 alkyl, -L-C 3 _i 0 aryl, - L-Ci-iohetaryl, -L-C 3 _i 0 cycloalkyl, or -L-Ci_i 0 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 22 is-L-C M oalkyl, -L-C 3 . 10 aryl, -L-Ci.i 0 hetaryl, - L-C 3 . 10 cycloalkyl, or -L-C M oheterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 3 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M oalkyl, -C 2 . 10 alkenyl, or -C 2 . 10 alkynyl.
  • R 3 is hydrogen, halogen, -OH, - CF 3 , or -Ci-ioalkyl.
  • R 3 ' is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -Ci-ioalkyl, -C 2 _i 0 alkenyl, or -C 2 -i 0 alkynyl.
  • R 3 ' is hydrogen, halogen, -OH, - CF 3 , or -C M oalkyl.
  • oalkoxy-C M oheterocyclyl -C 3 _ 10 aryl-C M oalkyl, -C 3 . 10 aryl-C 2 . 10 alkenyl, -C 3 . 10 aryl-C 2 . 10 alkynyl, -C 3 . 10 aryl-C 3 . 10 hetaryl, -C 3 . 10 aryl-C 3 . 10 cycloalkyl, -C 3 _ 10 aryl-C M oheterocyclyl, -C M ohetaryl-C M oalkyl, -C ⁇ 10 hetaryl-C 2 .
  • oaryl -C M ohetaryl, -C 3 . 10 cycloalkyl, or -Ci-ioheterocyclyl, each of which is unsubstituted or substituted by one or more independent R 13 substituents.
  • R 4 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , -N0 2 , -CN, -S(O) 0 - 2 R 31 , -Ci-ioalkyl, -C 2 -ioalkenyl, or -C 2 -ioalkynyl.
  • R 4 is hydrogen, halogen, -OH, - CF 3 , or -Ci-i 0 alkyl.
  • R 5 is hydrogen, halogen, or -Cn 0 alkyl.
  • R 5 is hydrogen.
  • R 6 is -Ci_i 0 alkyl, -C 2 _i 0 alkenyl, -C 2 _i 0 alkynyl, -Ci_ 10 heteroalkyl, -C 3 _i 0 aryl, -C M ohetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 aikyl-C 3 -i 0 aryl, -Ci_ 10 alkyl-Ci-i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 2 .i 0 alkenyl-C 3 .i 0 aryl, -C 2 .i 0 alkenyl-C 3 .i 0 aryl,
  • R 6 is -C M oalkyl, -C 3 . 10 aryl, -C ! . 10 hetaryl, -C 3 _ 10 cycloalkyl, -C M oheterocyclyl, -C M oalkyl- C 3 .
  • R 6 is -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -Ci_ 10 alkyl-C 3 .ioaryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -Ci_ 10 heterocyclyl-Ci-ioalkyl, or -Ci.ioheterocyclyl-C 3 .ioaryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • R 6 is -Ci_i 0 alkyl, -Ci_ 10 heterocyclyl, -C M oalkyl-C 3 -i 0 aryl, -C M oheterocyclyl-C M oalkyl, or -Ci.ioheterocyclyl-C 3 .ioaryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • each of R 71i R 81 and R 91 is independently hydrogen, halogen, -CMO alkyl, -C 2 -ioalkenyl, -C 2 -w alkynyl, -Ci_i 0 heteroalkyl, -C 3 .i 0 aryl, -Ci_i 0 hetaryl, -C 3 .
  • each of R 71 R 81 and R 91 is independently hydrogen, halogen, or - CMO alkyl.
  • each of R 71i R 81 and R 91 is independently hydrogen.
  • each of R 72 , R 82 and R 92 is independently hydrogen, -CMO alkyl, -C 3 _i 0 aryl, - C 3 .
  • each of R 72 , R 82 and R 92 is independently hydrogen or -C M0 alkyl. In some embodiments, each of R 72 , R 82 and R 92 is independently hydrogen.
  • each of R 10 and R 14 is independently -CMO alkyl, -C 2 _ 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 . 10 cycloalkyl, -C M oheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 . 10 aryl, -C M0 hetaryl, or -C M oheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R u , R 12i R 13 and R 15 is independently hydrogen, halogen, -C O alkyl, -C 2 _i 0 alkenyl, -C 2 _i 0 alkynyl, -Ci-i 0 heteroalkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 .
  • each of R u , R 12, R 13 and R 15 is independently hydrogen, halogen, -C H0 alkyl, -OH, -CF 3 , -OR 3 , -NR 31 R 32 , -N0 2 , -CN, or - S(0)o- 2 R 31 .
  • each of Ru, Ri 3 ⁇ 4 Ri 3 and R15 is independently hydrogen, halogen, Cno alkyl, -OH or -CF 3 .
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen, -Cm alkyl, -C 3 . 10 aryl, or -C 3 _ 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen, -Cm alkyl, -C 3 . 10 aryl, or -C 3 _ 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • R 31 , R 32 , R 3"3 and R 3 ⁇ 4 is independently hydro gen or -Ci_i 0 alkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen or -Ci_ l oalkyl.
  • X 2 is NRi or CRA'
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 21i and X 10 is N or CR 91 ;
  • Ri is -Ci-ioalkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 alkyl-C 3 . 10 aryl, -Ci.i 0 alkyl-Ci.iohetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 3 _i 0 cycloalkyl- C M oalkyl, -C 3 .
  • Ri' is hydrogen, -Ci_i 0 alkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci_ i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci_i 0 aikyl-C 3 _iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 3 .
  • R6 is -Ci-ioalkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 alkyl-C 3 .
  • each of R 10 and R 14 is independently -CMO alkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, - C M0 heteroalkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 . 10 cycloalkyl, or -C M oheterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R , R and R is independently hydrogen, -C O alkyl, -C 3 . 10 aryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • X 2 is NRi or CRA '
  • X 3 is CR 3 R 3 '
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is NR 72 or CR 71
  • X 8 is N
  • X 9 is NR 21 or CR 21
  • X 10 is N or CR 91
  • Ri is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -C M oalkyl-C 3 .i 0 aryl, -Ci-ioalkyl-Ci-iohetaryl, -Ci-ioalkyl-C 3 .
  • Ri ' is hydrogen -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci_ 10 alkyl-C3_iocycloalkyl, -Ci-ioalkyl-Ci-ioheterocyclyl, -C M oheterocyclyl-C M oalkyl, or -Ci_i 0 heterocyclyl- C 3 _ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • R6 is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-i 0 alkyl-C 3 .
  • each of R 10 and R 14 independently -CMO alkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 . 10 cycloalkyl, or -C ⁇ 10 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R , R and R is independently hydrogen or -CM 0 alkyl, or wherein R together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • R 5 is hydrogen, halogen, or -Cm alkyl
  • R 6 is -C M oalkyl, -C M oheterocyclyl, -C M oalkyl-Quoaryl, -C M oheterocyclyl-C M oalkyl, or -C ⁇ 10 heterocyclyl-C3. 10 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -C MO alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, or -Ci_i 0 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u , R 12 and R 15 is independently hydrogen, halogen, -C MO alkyl, -OH, -CF 3 , -OR 3 , - NR 31 R 32 , -NO2, -CN, or -S(O) 0 - 2 R 31 ;
  • each of R , R and R is independently hydrogen or -C O alkyl, or wherein R together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • X 3 is CR 3 R 3 ' , Y is CR 5 ,
  • X 4 is CR 4 ,
  • X 5 is C,
  • X 6 is C,
  • X 7 is NR 72 ,
  • X 8 is N,
  • X 9 is CR 21, and
  • X 10 is N;
  • Ri is -C M oalkyl, -C M0 heterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 heterocyclyl-C M0 alkyl, or -C ⁇ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or Ru substituents;
  • R 21 is halogen, -CN, , -L-Ci.i 0 alkyl, -L-C 3 _ 10 aryl, -L-Ci_i 0 hetaryl, -L-C 3 . 10 cycloalkyl, or -L-Ci. 10 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents;
  • each of R 3 R 3 ' and R 4 is independently hydrogen, halogen, -OH, -CF 3 , or -Ci.i 0 alkyl; or R 3 ' is - OR 6 or -NR 6 R 34 , wherein R 6 together with R 34 can optionally form a heterocyclic ring;
  • R5 is hydrogen
  • R6 is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or -Ci_ 10 heterocyclyl-C3_ioaryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 _ioaryl, -Ci-iohetaryl, or -Ci_i 0 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u , R 12 and R 15 is independently hydrogen, halogen, -CMO alkyl, -OH or -CF 3 ;
  • each of R 31 and R 34 is independently hydrogen or -CMO alkyl
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • the invention also provides a compound as defined above, wherein the compound is of Formula I-B:
  • X 2 is NRi or CRiRi '
  • X 3 is CR 3 R 3 '
  • X 2 is NR 1
  • X 2 is CR ⁇ '
  • X 3 is CR 3 R 3 '
  • X 2 is NR 1
  • X 3 is CR 3 R 3 '
  • W is C
  • Y is CR 5 X 4 is N or CR 4
  • X 5 is C and X 6 is C.
  • W is C
  • Y is CR 5 X 4 is CR 4
  • X 5 is N or C and X 6 is C.
  • W is C
  • Y is CR 5 X 4 is CR 4 , X 5 is C and X 6 is C.
  • W is C
  • Y is CR 5 X 4 is CR 4
  • X 5 is N and X 6 is C.
  • W is C
  • Y is CR 5 X 4 is CR 4
  • X 5 is C and X 6 is N.
  • W is N
  • X 7 is NH, X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is N and X 8 is CR 8 i and X 9 is CR 2 i. In some embodiments, X 7 is CR 7 i, X 8 is N and X 9 is NR 22 . In some embodiments, X 7 is CR 7 i, X 8 is N and X 9 is CR 2 i. In some embodiments, X 7 is O, X 8 is N and X 9 is CR 2 i. In some embodiments, X 7 is O, X 8 is CR 8 and X 9 is NR 22 .
  • X 2 is N i or CRiRi '
  • W is N or C
  • Y is N or CR 5
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 21 .
  • X 2 is N i or CRiRi '
  • X 3 is CR 3 R 3 '
  • W is C
  • Y is CR 5
  • X 4 is N or CR
  • X5 is N or C
  • Xe is C
  • X 7 is NR 72 or CR 7 i
  • X 8 is N
  • X 9 is NR 22 or CR 2 i.
  • X 2 is NRi
  • X 3 is CR 3 R 3 '
  • W is C
  • Y is CR 5
  • X 4 is CR 4
  • X 5 is C
  • X 6 is C
  • X 7 is NR 72
  • X 8 is N
  • X 9 is CR 21 .
  • Ri is -C M oalkyl, -C 2 -i 0 alkenyl, -C 2 -i 0 alkynyl, -Ci_ 10 heteroalkyl, -C 3 .i 0 aryl, -C M ohetaryl, -C 3 .i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci_ 10 alkyl-Ci-i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 2 -ioalkenyl-C 3 .i 0 aryl, -C 2 .ioalkenyl-C 3 .i 0 aryl, -C 2 .
  • Ri is -Ci_i 0 alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _iocycloalkyl, -Ci_i 0 heterocyclyl, -Ci_i 0 alkyl- C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 3 .
  • Ri is -Ci_i 0 alkyl, -Ci_i 0 heterocyclyl, -Ci_ 10 alkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci.i 0 alkyl-C 3 .i 0 cycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -Ci_ 10 heterocyclyl-Ci-ioalkyl, or -Ci-ioheterocyclyl-C 3 -i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • R x is -C M oalkyl, -C ⁇ 10 heterocyclyl, -C M oalkyl-C 3 _ 10 aryl, -C M oheterocyclyl-C M oalkyl, or -C M oheterocyclyl-C 3 _ 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • R x ' is hydrogen, -C oalkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 . 10 cycloalkyl, -C M oheterocyclyl, -C M oalkyl-C 3 _ 10 aryl, -C ⁇ !
  • oalkyl-C M ohetaryl -C M oalkyl-C 3 _ 10 cycloaikyl, -C M oalkyl-C M oheterocyclyl, -C 2 . 10 alkenyl-C 3 . 10 aryl, -C 2 . ! oalkenyl-C M ohetaryl, -C 2 _ 10 arkenyl-C 3 _ 10 cycloarkyl, -C 2 _ 10 arkenyl-C M oheterocyclyl, -C 2 . 10 alkynyl-C 3 .
  • R ⁇ is hydrogen, -Ci_i 0 alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _iocycloalkyl, -Ci_i 0 heterocyclyl, -C M oalkyl-Cs.ioaryl, -C M oalkyl-C M ohetaryl, -C M oalkyl-Cs ⁇ ocycloalkyl, -C oalkyl-C M oheterocyclyl, - Cs.iocycloalkyl-C M oalkyl, -Cs.iocycloalkyl-Cs.ioaryl, -Cs ⁇ ocycloalkyl-C M ohetaryl, -Cs ⁇ ocycloalkyl-C !
  • R x ' is hydrogen, -Ci.i 0 alkyl, -C ⁇ 10 heterocyclyl, -C M oalkyl-Cs- !
  • Rj' is hydrogen, -Ci.i 0 alkyl, -C M oheterocyclyl, -C M oaikyl-Cs ⁇ oaryl, -C M oheterocyclyl-C M oalkyl, or - Ci.ioheterocyclyl-C 3 .ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • R 21 is halogen, -CN, , -L-C ⁇ oalkyl, -L-C 3 . 10 aryl, - L-C ⁇ ohetaryl, -L-C 3 . 10 cycloalkyl, or -L-C M oheterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 2 2 is-L-Ci_i 0 alkyl, -L-C 3 -i 0 aryl, -L-Ci-iohetaryl, - L-C 3 _iocycloalkyl, or -L-Ci_i 0 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • oalkoxy-C M oheterocyclyl -Q.ioaryl-C M oalkyl, -C 3 . 10 aryl-C 2 . 10 alkenyl, -C 3 . 10 aryl-C 2 . 10 alkynyl, -C 3 . 10 aryl-C 3 . 10 hetaryl, -C 3 . 10 aryl-C 3 . 10 cycloalkyl, -C ⁇ oaryl-C ⁇ oheterocyclyl, -C M ohetaryl-C M oalkyl, -C ⁇ 10 hetaryl-C 2 .
  • R 3 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -Ci-ioalkyl, -C 2 -i 0 alkenyl, or -C 2 -i 0 alkynyl.
  • R 3 is hydrogen, halogen, -OH, - CF 3 , or -Ci-ioalkyl.
  • R 3 ' is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M0 alkyl, -C 2 . 10 alkenyl, or -C 2 _ 10 aikynyl.
  • R 3 ' is hydrogen, halogen, -OH, - CF 3 , or -C M oalkyl.
  • R 4 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M oalkyl, -C 2 . 10 alkenyl, or -C 2 . 10 alkynyl.
  • R 4 is hydrogen, halogen, -OH, - CF 3 , or -C oalkyl.
  • R5 is hydrogen, halogen, C MO alkyl,— C 2 _ioalkenyl,— C 2 _io alkynyl, -C M0 heteroalkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 .
  • R 5 is hydrogen, halogen, or -CMO alkyl. In some embodiments, R 5 is hydrogen.
  • R 6 is -Ci_i 0 alkyl, -C 2 -i 0 alkenyl, -C 2 _i 0 alkynyl, -Ci_ 10 heteroalkyl, -C 3 .i 0 aryl, -C M ohetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci_ !
  • oalkyl-C M ohetaryl -C M oalkyl-C 3 _ 10 cycloaikyl, -C M oalkyl-C M oheterocyclyl, -C 2 . 10 alkenyl-C 3 . 10 aryl, -C 2 . 10 alkenyl -C M ohetaryl, -C 2 . 10 alkenyl-C 3 . 10 cycloalkyl, -C 2 _ 10 arkenyl-C M oheterocyclyl, -C 2 . 10 alkynyl-C 3 .
  • R 6 is -Ci_i 0 alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _iocycloalkyl, -Ci_i 0 heterocyclyl, -Ci_i 0 alkyl- C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 3 .
  • R 6 is -C M oalkyl, -C M oheterocyclyl, -C ⁇ 10 alkyl-C 3 .
  • R 6 is -C M oalkyl, -C ⁇ 10 heterocyclyl, -C M oalkyl-C 3 _ 10 aryl, -C oheterocyclyl-C M oalkyl, or -C M oheterocyclyl-C 3 _ 10 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • each of R 71 R 81 and R 91 is independently hydrogen, halogen, -CMO alkyl, -C 2 . 10 alkenyl, -C 2 _ 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C ! . 10 hetaryl, -C 3 .
  • each of R 71 R 81 and R 91 is independently hydrogen, halogen, or - CMO alkyl.
  • each of R 71i R 81 and R 91 is independently hydrogen.
  • each of R 72 , R 82 and R 92 is independently hydrogen, Ci_io alkyl, -C 2 . 10 alkenyl, -C 2 -w alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .
  • each of R 72 , R 82 and R 92 is independently hydrogen, -CMO alkyl, -C 3 .
  • each of R 72 , R 82 and R 92 is independently hydrogen, -CMO alkyl, -C 3 . 10 aryl, - C 3 .
  • each of R 72 , R 82 and R 92 is independently hydrogen or -C M0 alkyl. In some embodiments, each of R 72 , R 82 and R 92 is independently hydrogen.
  • each of R 10 and R 14 is independently -C O alkyl, -C 2 . 10 alkenyl, -C2-10 alkynyl, -Ci-i 0 heteroalkyl, -C 3 _i 0 aryl, -Ci-iohetaryl, -C 3 _i 0 cycloalkyl, -Ci-ioheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 _i 0 aryl, -Ci-iohetaryl, -C 3 _i 0 cycloalkyl, or -Ci-ioheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 _i 0 aryl, -Ci-iohetaryl, or -Ci-ioheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R u , R 12i R 13 and R 15 is independently hydrogen, halogen, -CMO alkyl, -C 2 _i 0 alkenyl, -C2-10 alkynyl, -Ci-i 0 heteroalkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 .
  • each of R u , R 12, R 13 and R 15 is independently hydrogen, halogen, -CMO alkyl, -OH, -CF 3 , -OR 3 , -NR 31 R 32 , -N0 2 , -CN, or - S(0)o- 2 R 31 .
  • each of Ru, Ri 3 ⁇ 4 Ri 3 and R15 is independently hydrogen, halogen, CMO alkyl, -OH or -CF 3 . 31 32 33 34
  • each of R , R , R and R is independently hydrogen, halogen, -C M0 alkyl, -C 2 -ioalkenyl, -C 2 -w alkynyl, -Ci_i 0 heteroalkyl, -C 3 .i 0 aryl, -Ci-iohetaryl, -C 3 . 10 cycloalkyl, -Ci_i 0 heterocyclyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R , R , R and R is independently hydrogen, -Cm alkyl, -C 3 _ioaryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R , R , R and R is independently hydrogen, -Cm alkyl, -C 3 _ioaryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • R , R , R" and R ⁇ is independently hydro gen or -Ci_i 0 alkyl, or wherein R together with R form a
  • each of R , R , R and R is independently hydrogen or -C ⁇ l oalkyl.
  • X 2 is NRi or CR ⁇ '
  • W is C
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 21
  • X 10 is N or CR 91 ;
  • Ri is -C M oalkyl, -C 3 . 10 aryl, -C ! . 10 hetaryl, -C 3 . 10 cycloalkyl, -C M oheterocyclyl, -C M oalkyl-Q. 10 aryl, -C M oalkyl-C M ohetaryl, -C M oalkyl-C ⁇ ocycloalkyl, -C M oalkyl-C ⁇ oheterocyclyl, -C 3 .
  • Ri ' is hydrogen, -Ci_i 0 alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _iocycloalkyl, -Ci_i 0 heterocyclyl, -Ci_ ioalkyl-C 3 .i 0 aryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci.i 0 alkyl-Ci.i 0 heterocyclyl, -C 3 .
  • R6 is -Ci_i 0 alkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 alkyl-C 3 . 10 aryl, -C M oalkyl-C M ohetaryl, -C M oalkyl-C 3 _ 10 cycloaikyl, -C oalkyl-C M oheterocyclyl, -C 3 . 10 cycloalkyl- C M oalkyl, -C 3 .
  • each of R 10 and R 14 is independently -C MO alkyl, -C 2 -ioalkenyl, -C 2 . 10 alkynyl, - C M0 heteroalkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 . 10 cycloalkyl, or -C M oheterocyclyl, optionally substituted by one or more independent R n substituents;
  • each of R , R and R is independently hydrogen, -C MO alkyl, -C 3 _i 0 aryl, or -C 3 _i 0 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • X 2 is NRi or CRA '
  • X 3 is CR 3 R 3 '
  • W is C
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is NR 72 or CR 71
  • X 8 is N
  • X 9 is NR 21 or CR 21
  • X 10 is N or CR 91 ;
  • Ri is -C M0 alkyl, -C M0 heterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 alkyl-C M0 hetaryl, -C M0 alkyl-C 3 . 10 cycloalkyl, -C M oalkyl-C M oheterocyclyl, -C M0 heterocyclyl-C M0 alkyl, or -C M0 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • Ri' is hydrogen -Ci.i 0 alkyl, -C M oheterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 alkyl-C M0 hetaryl, -C ⁇ 10 alkyl-C 3 . 10 cycloalkyl, -C M0 alkyl-C M0 heterocyclyl, -C M oheterocyclyl-C M oalkyl, or -C M oheterocyclyl- C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • R 6 is -Ci-ioalkyl, -C M oheterocyclyl, -C M oalkyl-C 3 _ 10 aryl, -C oalkyl-C M ohetaryl, -C M c>alkyl-C 3 _ 10 cycloalkyl, -C M oalkyl-C M oheterocyclyl, -C M oheterocyclyl-C M oalkyl, or -C M oheterocyclyl-C 3 _ 10 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 independently -C MO alkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 . 10 cycloalkyl, or -C ⁇ 10 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R 31 , R 32 and R 34 is independently hydrogen or -C MO alkyl, or wherein R 31 together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • X 2 is NR 1 ;
  • X 3 is CR 3 R 3 ', W is C, Y is CR 5 ,
  • X 4 is CR 4 ,
  • X 5 is C,
  • X 6 is C,
  • X 7 is NR 72 ,
  • X 8 is N,
  • X 9 is CR 21i and X 10 is N or CR 91 ;
  • Ri is -Ci-ioalkyl, -Ci-i 0 heterocyclyl, -C M0 alkyl-C 3 .i 0 aryl, -C M0 heterocyclyl-C M0 alkyl, or -Ci_ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • R5 is hydrogen, halogen, or -C O alkyl
  • R6 is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or -Ci_ 10 heterocyclyl-C3_ioaryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 _ioaryl, -Ci-iohetaryl, or -Ci_i 0 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u , R 12 and R 15 is independently hydrogen, halogen, -CMO alkyl, -OH, -CF 3 , -OR 3 , - NR 31 R 32 , -N0 2 , -CN, or -S(O) 0 - 2 R 31 ;
  • each of R , R and R is independently hydrogen or -CMO alkyl, or wherein R together with R 32 form a heterocyclic ring;
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • X 2 is NR 1 ;
  • X 3 is CR 3 R 3 ' , W is C,
  • Y is CR 5 ,
  • X 4 is CR 4 ,
  • X 5 is C,
  • X 6 is C,
  • X 7 is NR 72 ,
  • X 8 is N,
  • X 9 is CR 21i and X 10 is N;
  • Ri is -C M oalkyl, -C M0 heterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 heterocyclyl-C M0 alkyl, or -C ⁇ 10 heterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • R 21 is halogen, -CN, , -L-C M oalkyl, -L-C 3 _i 0 aryl, -L-Ci-i 0 hetaryl, -L-C 3 _i 0 cycloalkyl, or -L-Ci_ 10 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents;
  • each of R 3i R 3 ' and R 4 is independently hydrogen, halogen, -OH, -CF 3 , or -Ci-i 0 alkyl; or R 3 ' is - OR 6 or -NR 6 R 34 , wherein R 6 together with R 34 can optionally form a heterocyclic ring;
  • R5 is hydrogen
  • R 6 is -C M oalkyl, -C M0 heterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 heterocyclyl-C M0 alkyl, or -C ⁇ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -CM 0 alkyl, -C 3 . 10 aryl, -C M ohetaryl, or -C M oheterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u , R 12 and R 15 is independently hydrogen, halogen, -CMO alkyl, -OH or -CF 3 ;
  • each of R 31 and R 34 is independently hydrogen or -C O alkyl
  • ring A comprises one or more heteroatoms selected from N, O, or S.
  • the invention also provides a compound as defined above, wherein the compound is of Formula II:
  • X x is S0 2 , X 2 is NRi, and X 3 is CR 3 R 3 ' .
  • W is C, Y is CR 5 , X 4 is N or CR 4 , X 5 is C and X 6 is C.
  • W is C, Y is CR 5 , X 4 is CR 4 , X 5 is N or C and X 6 is C.
  • W is C, Y is CR 5 , X 4 is CR 4 , X 5 is C and X 6 is C.
  • W is C, Y is CR 5 , X 4 is CR 4 , X 5 is N and X 6 is C.
  • W is C
  • Y is CR 5
  • X 4 is CR 4
  • X 5 is C and X 6 is N.
  • W is N
  • X 5 is C and X 6 is C.
  • W is N
  • X 5 is C and X 6 is N.
  • X 7 is NH, X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is N and X 8 is CR 81 and X 9 is CR 21 . In some embodiments, X 7 is CR 7 , X 8 is N and X 9 is NR 22 . In some embodiments, X 7 is CR 7 , X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is O, X 8 is N and X 9 is CR 2 . In some embodiments, X 7 is O, X 8 is CR 8 i and X 9 is NR 2 i.
  • X 2 is N i or CRiRi'
  • W is N or C
  • Y is N or CR 5
  • X 4 is N
  • C 0 or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 21 .
  • X 2 is NRi or CRiRi '
  • X 3 is CR 3 R 3 '
  • W is C
  • Y is CR 5
  • X 4 is N or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is NR 72 or CR 71
  • X 8 is N
  • X 9 is NR 22 or CR 21 .
  • Ri is-Ci_i 0 alkyl, -C 3 .i 0 aryl, -Ci-iohetaryl, -C 3 . 10 cycloalkyl, - C M oheterocyclyl, -C M oalkyl-C 3 _ 10 aryl, -C M oalkyl-C M ohetaryl, -C M oalkyl-C ⁇ ocycloalkyl, -C M oalkyl- C M oheterocyclyl, -Q.iocycloaikyl-C M oalkyl, -C ⁇ ocycloalkyl-C ⁇ oaryl, -C 3 _ 10 cycioaikyl-C M ohetaryl, - Cs.iocycloalkyl-C M oheterocyclyl, -C M oheterocyclyl
  • Rj is -Ci.ioalkyl, - C M oheterocyclyl, -C M0 alkyl-C 3 _ 10 aryl, -Ci_ioalkyl-Ci_i 0 hetaryl, -C M0 alkyl-C 3 .
  • Ri is -Ci.ioalkyl, -C M oheterocyclyl, -C M0 alkyl-C 3 .
  • Formula II is hydrogen, -Ci-ioalkyl, -C 3 -ioaryl, -Ci-iohetaryl, -C 3 . 10 cycloalkyl, -Ci-ioheterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci-ioalkyl-Ci-iohetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci-ioalkyl-Ci-ioheterocyclyl, -C 3 .iocycloalkyl-Ci.i 0 alkyl, -C 3 .iocycloalkyl-C 3 .i 0 aryl, -C 3 .i 0 cycloalkyl-Ci.
  • R x ' is hydrogen, - Ci.ioalkyl, -Ci.i 0 heterocyclyl, -Ci.ioalkyl-C 3 .ioaryl, -Ci.ioalkyl-Ci.iohetaryl, -Ci.ioalkyl-C 3 .iocycloalkyl, - Ci.ioalkyl-Ci.ioheterocyclyl, -Ci.ioheterocyclyl-Ci.ioalkyl, or -Ci.ioheterocyclyl-C 3 .ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • Rj' is hydrogen, -Ci.i 0 alkyl, -Ci.i 0 heterocyclyl, -Ci.ioalkyl-C 3 .ioaryl, -Ci.ioheterocyclyl-Ci.ioalkyl, or - Ci.ioheterocyclyl-C 3 .ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • R 21 is halogen, -CN, , -L-Ci.i 0 alkyl, -L-C 3 . 10 aryl, - L-C M ohetaryl, -L-C 3 . 10 cycloalkyl, or -L-C M oheterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 22 is- L-Ci-ioalkyl, -L-C 3 _ioaryl, -L-Ci-iohetaryl, -L-C 3 _iocycloalkyl, or -L-Ci-i 0 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 3 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M oalkyl, -C 2 _ 10 alkenyl, or -C 2 _ 10 alkynyl.
  • R 3 is hydrogen, halogen, -OH, -CF 3 , or -Ci-i 0 alkyl.
  • R 3 ' is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M oalkyl, -C 2 _ 10 alkenyl, or -C 2 _ 10 alkynyl.
  • R 3 ' is hydrogen, halogen, -OH, -CF 3 , or -C oalkyl.
  • R 4 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , -NO 2 , -CN, -S(0)o- 2 R 31 , -C M oalkyl, -C 2 -i 0 alkenyl, or -C 2 -ioalkynyl.
  • R 4 is hydrogen, halogen, -OH, -CF 3 , or -C M oalkyl.
  • R 5 is hydrogen, halogen, or -C MO alkyl.
  • R 5 is hydrogen.
  • R 6 is -C M0 alkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 . 10 cycloalkyl, -C M oheterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 alkyl-C M0 hetaryl, -C M0 alkyl-C 3 . 10 cycloalkyl, -C M0 alkyl- C M oheterocyclyl, -C 3 .
  • R 6 is -C M0 alkyl, - CMoheterocyclyl, -CM 0 alkyl-C 3 .i 0 aryl, -CM 0 alkyl-CM 0 hetaryl, -CM 0 alkyl-C 3 .i 0 cycloalkyl, -Ci-i 0 alkyl- Ci-ioheterocyclyl, -Ci-ioheterocyclyl-Ci-ioalkyl, or -C M oheterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • R 6 is -Ci-ioalkyl, -C M oheterocyclyl, -C M0 alkyl-C 3 .i 0 aryl, -Ci-ioheterocyclyl-Ci-ioalkyl, or -Ci_ 10 heterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • each of R 71 and R 81 is independently hydrogen, halogen, or C MO alkyl.
  • each of R 71 and R 81 is independently hydrogen.
  • each of R 72 and R 82 is independently hydrogen or -C M0 alkyl. In some embodiments, each of R 72 and R 82 is independently hydrogen.
  • each of R 10 and R 14 is independently -C MO alkyl, -C 2 . 10 alkenyl, -C 2 - 10 alkynyl, -Ci-i 0 heteroalkyl, -C 3 _i 0 aryl, -Ci-iohetaryl, -C 3 _i 0 cycloalkyl, -Ci-ioheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R 10 and R 14 is independently -C MO alkyl, -C 3 _ioaryl, -Ci-iohetaryl, -C 3 _iocycloalkyl, or -Ci-ioheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R 10 and R 14 is independently -C MO alkyl, -C 3 _ioaryl, -Ci-iohetaryl, or -Ci_i 0 heterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R u , R 12, R 13 and R 15 is independently hydrogen, halogen, -C MO alkyl, -OH, -CF 3 , -OR 3 , -NR 31 R 32 , -N0 2 , -CN, or - S(0)o- 2 R 31 .
  • each of Ru, Ri 3 ⁇ 4 Ri 3 and R 15 is independently hydrogen, halogen, C MO alkyl, -OH or -CF 3 .
  • each of R 31 , R 32 , R 33 and R 34 is independently selected from the group consisting of R 31 , R 32 , R 33 and R 34.
  • [0238] is independently hydrogen, halogen, -C MO alkyl, -C 2 . 10 alkenyl, -C 2 _ 10 alkynyl, -C M0 heteroalkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 _ 10 cycloalkyl, -C M0 heterocyclyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R 31 , R 32 , R 33 and R 34 is independently hydrogen, -C MO alkyl, -C 3 _i 0 aryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • R 31 , R 32 , R 3"3 and R 3"4" is independently hydro gen or -Ci-i 0 alkyl, or wherein R 31 together with R 32 form a heterocyclic ring.
  • each of R 31 , R 32 , and R 33 is independently hydrogen or -Ci_ l oalkyl.
  • X 2 is NRi or CRA'
  • W is N or C
  • Y is CR 5
  • X 4 is N
  • C 0 or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81 ,
  • Ri is -Ci-i 0 alkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci-i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 . 10 aryl, -C M0 alkyl-C M0 hetaryl, -C M0 alkyl-C 3 . 10 cycloalkyl, -C M0 alkyl-C M0 heterocyclyl, -C 3 . 10 cycloalkyl- C M0 alkyl, -C 3 . 10 cycloalkyl-C 3 .
  • Ri' is hydrogen, -Ci_i 0 alkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci_ 10 aikyl-C 3 _ 10 aryl, -C M0 aikyl-Ci_iohetaryl, -Ci_i 0 alkyl-C 3 .i 0 cycloalkyl, -C M0 alkyl-C M0 heterocyclyl, -C 3 .
  • R6 is -Ci-ioalkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, -C 3 _i 0 cycloalkyl, -Ci_i 0 heterocyclyl, -Ci-i 0 alkyl-C 3 .
  • each of R 10 and R 14 is independently -C MO alkyl, -C 2 . 10 alkenyl, -C 2 . 10 alkynyl, -L-Ci. 10 heteroalkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 . 10 cycloalkyl, or -C M oheterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R 31 , R 32 and R 34 is independently hydrogen, -C O alkyl, -C 3 . 10 aryl, or -C 3 . 10 cycloalkyl, or wherein R 31 together with R 32 form a heterocyclic ring;
  • X 5 , X 6 , X7, Xs or X 9 comprises one or more heteroatoms selected from N,
  • X 2 is N i or CRiRi'
  • X 3 is CR 3 R 3 '
  • W is N or C
  • Y is CR 5
  • X 4 is N
  • C 0 or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is NR 72 or CR 71
  • X 8 is N
  • X 9 is NR 2i or
  • Ri is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -C M oalkyl-C 3 .i 0 aryl, -Ci-ioalkyl-Ci-iohetaryl, -Ci-ioalkyl-C 3 . 10 cycloalkyl, -C M oalkyl-C M oheterocyclyl, -C M oheterocyclyl-C M oalkyl, or -Ci.ioheterocyclyl-C 3 .ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • Ri ' is hydrogen, -Ci.i 0 alkyl, -Ci.i 0 heterocyclyl, -Ci.ioalkyl-C 3 .ioaryl, -Ci.ioalkyl-Ci.iohetaryl, - Ci.io lkyl-C 3 .iocycloalkyl, -Ci.ioalkyl-Ci.ioheterocyclyl, -Ci.ioheterocyclyl-Ci.ioalkyl, or -C ⁇ 10 heterocyclyl-C3. 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or Ru substituents;
  • R 6 is -Ci-ioalkyl, -C M oheterocyclyl, -C M oalkyl-C 3 _ 10 aryl, -C oalkyl-C M ohetaryl, -C oalkyl-C 3 _ 10 cycloalkyl, -C M oalkyl-C M oheterocyclyl, -C M oheterocyclyl-C M oalkyl, or -C M oheterocyclyl-C 3 _ 10 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 . 10 aryl, -C M0 hetaryl, -C 3 . 10 cycloalkyl, or - C M oheterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R , R and R is independently hydrogen or -CMO alkyl, or wherein R together with R 32 form a heterocyclic ring; and wherein at least one of X 5 , X 6 , X7, Xs or X 9 comprises one or more heteroatoms selected from N,
  • Ri is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci-ioalkyl-C 3 .ioaryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or -Ci_ 10 heterocyclyl-C3_ioaryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents;
  • R 5 is independently hydrogen, halogen, or -CMO alkyl
  • R6 is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or -Ci_ 10 heterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • R 72 is hydrogen or -Ci_i 0 alkyl
  • each of R 10 and R 14 is independently -CMO alkyl, -C 3 _i 0 aryl, -Ci_i 0 hetaryl, or -Ci_i 0 heterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u and Ri 2 is independently hydrogen, halogen, -CMO alkyl, -OH, -CF 3 , -OR 3 , -NR 31 R 32 , - N0 2 , -CN, or -S(O) 0 - 2 R 31 ;
  • each of R , R and R is independently hydrogen or -CMO alkyl, or wherein R together with R 32 form a heterocyclic ring;
  • X 5 , X 6 , X 7 , X 8 or X 9 comprises one or more heteroatoms selected from N,
  • Ri is -C M oalkyl, -C M0 heterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 heterocyclyl-C M0 alkyl, or -C ⁇ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or Ru substituents;
  • R 21 is halogen, -CN, , -L-Ci_i 0 alkyl, -L-C 3 _i 0 aryl, -L-Ci_i 0 hetaryl, -L-C 3 _i 0 cycloalkyl, or -L-Ci_ 10 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents;
  • R5 is hydrogen
  • R6 is -Ci-ioalkyl, -Ci_i 0 heterocyclyl, -Ci.i 0 alkyl-C 3 .i 0 aryl, -Ci.i 0 heterocyclyl-Ci.i 0 alkyl, or -Ci_ 10 heterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents;
  • each of R 10 and R 14 is independently -Cno alkyl, -C 3 . 10 aryl, -C M ohetaryl, or -C M oheterocyclyl, optionally substituted by one or more independent R u substituents;
  • each of R u , R 12 and R15IS independently hydrogen, halogen, -Cn 0 alkyl, -OH or -CF 3 ;
  • each of R 31 and R 34 is independently hydrogen or -Cn 0 alkyl
  • X 5 , X 6 , X 7 , X 8 or X 9 comprises one or more heteroatoms selected from N,
  • the invention also provides a compound as defined above, wherein the compound is of Formula
  • X x is S0 2 , X 2 is NRi, and X 3 is CR 3 R 3 ' .
  • Y is CR 5 , X 4 is N or CR , X5 is C and X 6 is C.
  • Y is CR 5 , X is CR , X5 is N or C and X 6 is C.
  • Y is CR 5 , X is CR , X 5 is C and X 6 is C.
  • Y is CR 5 , X 4 is CR 4 , X 5 is N and X 6 is C.
  • Y is CR 5 , X 4 is CR 4 , X 5 is C and X 6 is N.
  • X 7 is NH, X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is N and X 8 is CR 81 and X 9 is CR 21 . In some embodiments, X 7 is CR 7 , X 8 is N and X 9 is NR 22 . In some embodiments, X 7 is CR 7 , X 8 is N and X 9 is CR 21 . In some embodiments, X 7 is O, X 8 is N and X 9 is CR 2 . In some embodiments, X 7 is O, X 8 is CR 81 and X 9 is NR 21 .
  • X 2 is N i or CRA '
  • Y is N or CR 5
  • X 4 is N
  • C 0 or CR 4
  • X 5 is N or C
  • X 6 is C
  • X 7 is N or NR 72 or CR 71
  • X 8 is N or CR 81
  • X 9 is NR 22 or CR 21 .
  • X 2 is N i or CR 1 R 1 '
  • X 3 is CR 3 R 3 '
  • Y is CR 5
  • X 4 is N or CR 4
  • X5 is N or C
  • Xe is C
  • X 7 is NR 72 or CR 71
  • X 8 is N
  • X 9 is NR 22 or CR 2 i.
  • X 2 is NRi
  • X 3 is CR3R3'
  • Y is CR 5
  • X 4 is CR 4
  • X 5 is C
  • X 6 is C
  • X 7 is NR 72
  • X 8 is N
  • X 9 is CR 21 .
  • Ri is-Ci-i 0 alkyl, -C 3 _ioaryl, -Ci_i 0 hetaryl, -C 3 _iocycloalkyl, -C M oheterocyclyl, -Ci.ioalkyl-C 3 .ioaryl, -Ci.i 0 alkyl-Ci.i 0 hetaryl, -Ci-ioalkyl-C 3 .iocycloalkyl, -Ci_i 0 alkyl- C M oheterocyclyl, -C 3 _iocycloalkyl-C M0 alkyl, -C 3 _iocycloalkyl-C 3 _i 0 aryl, -C 3 _iocycloalkyl-C M0 hetaryl, - C 3 _iocycloalkyl-C M0 hetaryl, - C 3 _i
  • Ri is -Ci_i 0 alkyl, - C M oheterocyclyl, -C M0 alkyl-C 3 .
  • Ri is -Ci.ioalkyl, -C M oheterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 heterocyclyl-C M0 alkyl, or -Ci_ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or Ru substituents.
  • R x ' is hydrogen, -Ci.ioalkyl, -C 3 _i 0 aryl, -Ci-iohetaryl, -C 3 .
  • R x ' is hydrogen, - Ci.ioalkyl, -d-ioheterocyclyl, -C M0 alkyl-C 3 .i 0 aryl, -C M0 alkyl-C M0 hetaryl, -C M0 alkyl-C 3 .i 0 cycloalkyl, - Ci-ioalkyl-Ci-ioheterocyclyl, -Ci-ioheterocyclyl-Ci-ioalkyl, or -C M oheterocyclyl-C 3 .i 0 aryl, each of which is unsubstituted or substituted by one or more independent R 10 or R u substituents.
  • Ri ' is hydrogen, -Ci.io lkyl, -Ci_i 0 heterocyclyl, -C M0 alkyl-C 3 .i 0 aryl, -C M0 heterocyclyl-C M0 alkyl, or - Ci_ioheterocyclyl-C 3 _i 0 aryl, each of which is unsubstituted or substituted by one or more independent R i0 or Ru substituents.
  • R 2 i is halogen, -CN, , -L-Ci_i 0 alkyl, -L-C 3 _ioaryl, - L-Ci-iohetaryl, -L-C 3 _iocycloalkyl, or -L-Ci_i 0 heterocyclyl, each of which is unsubstituted or substituted by one or more independent R 12 substituents.
  • R 22 is- F-C M oalkyl, -F-C 3 . 10 aryl, -F-C ! .
  • R 3 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M oalkyl, -C 2 _ 10 alkenyl, or -C 2 _ 10 alkynyl.
  • R 3 is hydrogen, halogen, -OH, -CF 3 , or -C oalkyl.
  • R 3 ' is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , - -NO 2 , -CN, -S(0)o- 2 R 31 , -Ci.i 0 alkyl, -C 2 -i 0 alkenyl, or -C 2 -ioalkynyl.
  • R 3 ' is hydrogen, halogen, -OH, -CF 3 , or -C oalkyl.
  • R 4 is hydrogen, halogen, -OH, -CF 3 , -OCF 3 , -OR 31 , -NR 31 R 32 , -N0 2 , -CN, -S(O) 0 - 2 R 31 , -C M oalkyl, -C 2 _ 10 alkenyl, or -C 2 _ 10 alkynyl.
  • R 4 is hydrogen, halogen, -OH, -CF 3 , or -Ci-i 0 alkyl.
  • R 5 is hydrogen, halogen, or -C M0 alkyl. In some embodiments, R 5 is hydrogen.
  • R 6 is -Ci_i 0 alkyl, -C 3 _i 0 aryl, -Ci-i 0 hetaryl, -C 3 _i 0 cycloalkyl, -C M oheterocyclyl, -Ci.ioalkyl-C 3 .i 0 aryl, -C M0 alkyl-C M0 hetaryl, -Ci-ioalkyl-C 3 .i 0 cycloalkyl, -Ci-i 0 alkyl- C M oheterocyclyl, -C 3 .
  • R 6 is -C M0 alkyl, - C M oheterocyclyl, -C M0 alkyl-C 3 .
  • aryl -C M0 alkyl-C M0 hetaryl, -C M0 alkyl-C 3 .
  • 10 cycloalkyl, -C M oalkyl- C M oheterocyclyl, -C M0 heterocyclyl-C M0 alkyl, or -C M0 heterocyclyl-C 3 .
  • R 6 is -C M oalkyl, -C M oheterocyclyl, -C M0 alkyl-C 3 . 10 aryl, -C M0 heterocyclyl-C M0 alkyl, or -C ⁇ 10 heterocyclyl-C 3 . 10 aryl, each of which is unsubstituted or substituted by one or more independent R 14 or R 15 substituents.
  • each of R 71 and R 81 is independently hydrogen, halogen, or -Cm alkyl.
  • each of R 71 and R 81 is independently hydrogen.
  • each of R 72 and R 82 is independently hydrogen or -C M oalkyl.
  • each of R 72 and R 82 is independently hydrogen.
  • each of R 10 and R 14 is independently -Cno alkyl, -C 2 _ 10 alkenyl, -C 2 . 10 alkynyl, -C M oheteroalkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 . 10 cycloalkyl, -C M oheterocyclyl, optionally substituted by one or more independent R u substituents.
  • each of R 10 and R 14 is independently -Cno alkyl, -C 3 . 10 aryl, -C M ohetaryl, -C 3 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PCT/US2014/059197 2013-10-03 2014-10-03 Inhibitors of erk and methods of use Ceased WO2015051341A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
BR112016006994A BR112016006994A8 (pt) 2013-10-03 2014-10-03 inibidores de erk, seus usos e composições farmacêuticas os compreendendo
KR1020167011270A KR20160081908A (ko) 2013-10-03 2014-10-03 Erk의 억제제 및 사용 방법
EP14850964.9A EP3052096B8 (en) 2013-10-03 2014-10-03 Inhibitors of erk and methods of use
CN201480054909.3A CN105636586B (zh) 2013-10-03 2014-10-03 Erk抑制剂及使用方法
JP2016546894A JP6427197B2 (ja) 2013-10-03 2014-10-03 Ｅｒｋの阻害剤および使用方法
US15/026,581 US9624228B2 (en) 2013-10-03 2014-10-03 Inhibitors of ERK and methods of use
LTEP14850964.9T LT3052096T (lt) 2013-10-03 2014-10-03 Erk inhibitoriai ir jų panaudojimo būdai
AU2014331628A AU2014331628B2 (en) 2013-10-03 2014-10-03 Inhibitors of ERK and methods of use
MEP-2018-90A ME02991B (me) 2013-10-03 2014-10-03 Ekr inhibitori i postupci primene
DK14850964.9T DK3052096T3 (en) 2013-10-03 2014-10-03 INHIBITORS OF ERK AND METHODS OF USE
ES14850964.9T ES2664794T3 (es) 2013-10-03 2014-10-03 Inhibidores de ERK y métodos de uso
SI201430659T SI3052096T1 (en) 2013-10-03 2014-10-03 EAQ inhibitors and application procedures
EP17204999.1A EP3363800A1 (en) 2013-10-03 2014-10-03 Heterocyclic inhibitors of erk and methods of use
SG11201602572YA SG11201602572YA (en) 2013-10-03 2014-10-03 Inhibitors of erk and methods of use
HRP20180538TT HRP20180538T1 (hr) 2013-10-03 2014-10-03 Inhibitori za erk i postupci njihove uporabe
PL14850964T PL3052096T3 (pl) 2013-10-03 2014-10-03 Inhibitory ERK i sposoby ich zastosowania
EA201690708A EA032196B1 (ru) 2013-10-03 2014-10-03 Ингибиторы erk и способы применения
SM20180205T SMT201800205T1 (it) 2013-10-03 2014-10-03 Inibitori di erk e metodi d'uso
RS20180373A RS57058B1 (sr) 2013-10-03 2014-10-03 Ekr inhibitori i postupci primene
CA2924584A CA2924584A1 (en) 2013-10-03 2014-10-03 Inhibitors of erk and methods of use
MX2016004163A MX2016004163A (es) 2013-10-03 2014-10-03 Inhibidores de erk y metodos de uso.
PH12016500432A PH12016500432A1 (en) 2013-10-03 2016-03-07 Inhibitors of erk and methods of use
IL244488A IL244488A0 (en) 2013-10-03 2016-03-08 Inhibitors of erk and methods of use
ZA2016/01701A ZA201601701B (en) 2013-10-03 2016-03-11 Inhibitors of erk and methods of use
US15/439,719 US9951078B2 (en) 2013-10-03 2017-02-22 Inhibitors of ERK and methods of use
US15/896,929 US10301317B2 (en) 2013-10-03 2018-02-14 Inhibitors of ERK and methods of use
CY20181100340T CY1120095T1 (el) 2013-10-03 2018-03-27 Αναστολεις της erk και μεθοδοι χρησης
AU2018250439A AU2018250439A1 (en) 2013-10-03 2018-10-18 Inhibitors of erk and methods of use
US16/370,718 US20190292194A1 (en) 2013-10-03 2019-03-29 Inhibitors of erk and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361886552P 2013-10-03 2013-10-03
US61/886,552 2013-10-03
US201462032446P 2014-08-01 2014-08-01
US62/032,446 2014-08-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/026,581 A-371-Of-International US9624228B2 (en) 2013-10-03 2014-10-03 Inhibitors of ERK and methods of use
US15/439,719 Continuation US9951078B2 (en) 2013-10-03 2017-02-22 Inhibitors of ERK and methods of use

Publications (1)

Publication Number Publication Date
WO2015051341A1 true WO2015051341A1 (en) 2015-04-09

Family

ID=52779215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/059197 Ceased WO2015051341A1 (en) 2013-10-03 2014-10-03 Inhibitors of erk and methods of use

Country Status (28)

Country Link
US (4) US9624228B2 (https=)
EP (2) EP3363800A1 (https=)
JP (2) JP6427197B2 (https=)
KR (1) KR20160081908A (https=)
CN (2) CN105636586B (https=)
AU (2) AU2014331628B2 (https=)
BR (1) BR112016006994A8 (https=)
CA (1) CA2924584A1 (https=)
CY (1) CY1120095T1 (https=)
DK (1) DK3052096T3 (https=)
EA (1) EA032196B1 (https=)
ES (1) ES2664794T3 (https=)
HK (1) HK1255851A1 (https=)
HR (1) HRP20180538T1 (https=)
HU (1) HUE036600T2 (https=)
IL (1) IL244488A0 (https=)
LT (1) LT3052096T (https=)
ME (1) ME02991B (https=)
MX (1) MX2016004163A (https=)
PH (1) PH12016500432A1 (https=)
PL (1) PL3052096T3 (https=)
PT (1) PT3052096T (https=)
RS (1) RS57058B1 (https=)
SG (1) SG11201602572YA (https=)
SI (1) SI3052096T1 (https=)
SM (1) SMT201800205T1 (https=)
WO (1) WO2015051341A1 (https=)
ZA (1) ZA201601701B (https=)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017222958A1 (en) * 2016-06-20 2017-12-28 Kura Oncology, Inc. Treatment of squamous cell carcinomas with inhibitors of erk
WO2018177781A1 (en) 2017-03-28 2018-10-04 Basf Se Pesticidal compounds
WO2019076336A1 (zh) * 2017-10-19 2019-04-25 江苏豪森药业集团有限公司 含吡唑基的三并环类衍生物、其制备方法和应用
US10301317B2 (en) 2013-10-03 2019-05-28 Kura Oncology, Inc. Inhibitors of ERK and methods of use
EP3643705A1 (en) 2018-10-24 2020-04-29 Basf Se Pesticidal compounds
WO2020102686A1 (en) * 2018-11-16 2020-05-22 California Institute Of Technology Erk inhibitors and uses thereof
WO2020200161A1 (zh) * 2019-04-02 2020-10-08 上海翰森生物医药科技有限公司 含吲唑基的三并环类衍生物的盐及其晶型
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
EP4198023A1 (en) 2021-12-16 2023-06-21 Basf Se Pesticidally active thiosemicarbazone compounds
WO2023156402A1 (en) 2022-02-17 2023-08-24 Basf Se Pesticidally active thiosemicarbazone compounds
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
EP4467535A1 (en) 2023-05-25 2024-11-27 Basf Se Lactam pesticidal compounds
WO2024240859A1 (en) 2023-05-25 2024-11-28 Basf Se Lactam pesticidal compounds
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025067459A2 (en) 2023-09-29 2025-04-03 D3 Bio (Wuxi) Co., Ltd. Therapies for the treatment of cancer
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
CN109761986B (zh) * 2017-11-10 2021-10-08 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
WO2022075445A1 (ja) * 2020-10-08 2022-04-14 株式会社Adeka ポリオレフィン系樹脂組成物、それを用いた成形品、及びポリオレフィン系樹脂組成物の製造方法

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
US4042704A (en) * 1976-03-18 1977-08-16 Sandoz, Inc. Benzindazoles
US4739762A (en) 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
WO1990005719A1 (en) 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5116843A (en) * 1987-01-17 1992-05-26 Boehringer Mannheim Gmbh Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use
US5195984A (en) 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
EP0606046A1 (en) 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
US5451233A (en) 1986-04-15 1995-09-19 Yock; Paul G. Angioplasty apparatus facilitating rapid exchanges
US5496346A (en) 1987-01-06 1996-03-05 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
WO1996027583A1 (en) 1995-03-08 1996-09-12 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en) 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
EP0780386A1 (en) 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
WO1998033768A1 (en) 1997-02-03 1998-08-06 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1999029667A1 (en) 1997-12-05 1999-06-17 Pfizer Limited Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
EP0931788A2 (en) 1998-01-27 1999-07-28 Pfizer Limited Metalloprotease inhibitors
WO1999052910A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. Bicyclic hydroxamic acid derivatives
WO1999052889A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US6596726B1 (en) * 1994-01-25 2003-07-22 Warner Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US20080227767A1 (en) * 1999-05-24 2008-09-18 Neurochem (International) Limited Methods and compounds for inhibiting amyloid deposits
US20100056800A1 (en) * 2008-08-27 2010-03-04 The Ohio State University Method of synthesizing 1h-indazole compounds
EP2455381A1 (en) * 2009-07-17 2012-05-23 Japan Tobacco, Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
WO2012170845A2 (en) * 2011-06-08 2012-12-13 Heffernan Michele L R Metabotropic glutamate receptor 5 modulators and methods of use thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791816R (fr) 1971-11-24 1973-05-23 Sandoz Sa Derives de la quinazolinone, leur preparation et medicaments contenant ces
US4352931A (en) 1980-05-22 1982-10-05 Siegfried Aktiengesellschaft Lin-benzoaminopurinols
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP3896309B2 (ja) * 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
US20050203063A1 (en) * 2003-09-12 2005-09-15 Raymond Deshaies Proteasome pathway inhibitors and related methods
US7244757B2 (en) 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
MX2008010635A (es) 2006-02-16 2008-10-28 Schering Corp Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
AR068046A1 (es) 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
WO2008156739A1 (en) 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
DK2217597T3 (da) 2007-10-01 2011-06-20 Comentis Inc Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
WO2009105500A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
EP2408448A4 (en) 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3536319A1 (en) 2010-10-29 2019-09-11 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014052566A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2014134772A1 (en) 2013-03-04 2014-09-12 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
US9745307B2 (en) 2013-04-30 2017-08-29 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3363800A1 (en) 2013-10-03 2018-08-22 Kura Oncology, Inc. Heterocyclic inhibitors of erk and methods of use
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
CN107001322B (zh) 2014-12-18 2020-07-28 默沙东公司 用于药物制剂的组合物
MX2017008078A (es) 2014-12-19 2017-09-28 Merck Sharp & Dohme Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Ｅｒｋ抑制劑

Patent Citations (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US3984556A (en) * 1973-01-19 1976-10-05 Sandoz, Inc. Alkyl-substituted-tricyclic quinazolinones for lowering blood pressure
US4042704A (en) * 1976-03-18 1977-08-16 Sandoz, Inc. Benzindazoles
US4739762A (en) 1985-11-07 1988-04-26 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4739762B1 (en) 1985-11-07 1998-10-27 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5451233A (en) 1986-04-15 1995-09-19 Yock; Paul G. Angioplasty apparatus facilitating rapid exchanges
US5496346A (en) 1987-01-06 1996-03-05 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5116843A (en) * 1987-01-17 1992-05-26 Boehringer Mannheim Gmbh Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5195984A (en) 1988-10-04 1993-03-23 Expandable Grafts Partnership Expandable intraluminal graft
WO1990005719A1 (en) 1988-11-23 1990-05-31 British Bio-Technology Limited Hydroxamic acid based collagenase inhibitors
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5879382A (en) 1989-08-24 1999-03-09 Boneau; Michael D. Endovascular support device and method
EP0606046A1 (en) 1993-01-06 1994-07-13 Ciba-Geigy Ag Arylsulfonamido-substituted hydroxamic acids
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US6596726B1 (en) * 1994-01-25 2003-07-22 Warner Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1996027583A1 (en) 1995-03-08 1996-09-12 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
WO1996033172A1 (en) 1995-04-20 1996-10-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
EP0780386A1 (en) 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en) 1996-08-23 1998-02-26 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998030566A1 (en) 1997-01-06 1998-07-16 Pfizer Inc. Cyclic sulfone derivatives
WO1998033768A1 (en) 1997-02-03 1998-08-06 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1998034918A1 (en) 1997-02-11 1998-08-13 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
WO1999029667A1 (en) 1997-12-05 1999-06-17 Pfizer Limited Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
EP0931788A2 (en) 1998-01-27 1999-07-28 Pfizer Limited Metalloprotease inhibitors
WO1999052889A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
WO1999052910A1 (en) 1998-04-10 1999-10-21 Pfizer Products Inc. Bicyclic hydroxamic acid derivatives
US20080227767A1 (en) * 1999-05-24 2008-09-18 Neurochem (International) Limited Methods and compounds for inhibiting amyloid deposits
US20100056800A1 (en) * 2008-08-27 2010-03-04 The Ohio State University Method of synthesizing 1h-indazole compounds
EP2455381A1 (en) * 2009-07-17 2012-05-23 Japan Tobacco, Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
WO2012170845A2 (en) * 2011-06-08 2012-12-13 Heffernan Michele L R Metabotropic glutamate receptor 5 modulators and methods of use thereof

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"Remingtons Pharmaceutical Sciences, 20th Ed.,", 2000, LIPPINCOTT WILLIAMS & WILKINS
AHN ET AL., METHODS IN ENZYMOLOGY, vol. 332, 2001, pages 417 - 431
AHN ET AL., MOLECULAR CELL, vol. 6, 2000, pages 1343 - 1354
ANDERSON, PHILIP O.; KNOBEN, JAMES E.; TROUTMAN, WILLIAM G,: "Handbook of Clinical Drug Data, Tenth Edition,", 2002, MCGRAW-HILL
BJORBAEK ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 18848
BUNDGARD, H.: "Design of Prodrugs", 1985, ELSEVIER, pages: 7 - 9,21-24
CHEN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 10952
DATABASE PUBCHEM [online] 1 December 2012 (2012-12-01), "SCHEMBL7846632", XP055331725, retrieved from NCBI Database accession no. CID 70205837 *
DATABASE PUBCHEM [online] 4 December 2007 (2007-12-04), "SCHEMBL7879101", XP055331726, retrieved from NCBI Database accession no. CID 18347999 *
DATABASE PUBCHEM [online] 8 February 2007 (2007-02-08), "4A-AZONIA-5,6,7,8-TETRAHYDROANTHRACENE", XP055331729, retrieved from NCBI Database accession no. CID 13481918 *
EDWARD B. ROCHE,: "Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "Bioreversible Carriers"
FREY; MULDER, CANCER RES., vol. 57, 1997, pages 628
GREENE; WUTS: "Protective Groups in Organic Synthesis, 3.sup.rd Ed.,", 1999, JOHN WILEY & SONS
HARDMAN, LIMBIRD AND GILMAN: "Goodman and Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition", .
HIGUCHI, T. ET AL.: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
HOSHINO, R. ET AL., ONCOGENE, vol. 18, 1999, pages 813 - 822
KATZUNG,: "Basic and Clinical Pharmacology, Ninth Edition", 2003, MCGRAW HILL
KHOKHLATCHEV ET AL., CELL, vol. 93, 1998, pages 605 - 615
KOHL ET AL., SCIENCE, vol. 260, 1993, pages 1834 - 1837
LEWIS ET AL., ADV. CANCER RES., vol. 74, 1998, pages 49 - 139
MARTINDALE: "The Extra Pharmacopoeia, Thirty-Second Edition", 1999, THE PHARMACEUTICAL PRESS
OLIVER ET AL., PROC. SOC. EXP. BIOL. MED., vol. 210, 1995, pages 162
PHYSICIAN'S DESK REFERENCE
PRATT AND TAYLOR: "Principles of Drug Action, Third Edition,", 1990, CHURCHILL LIVINGSTON
RAINGEAUD ET AL., MOL. CELL BIOL., vol. 16, 1996, pages 1247
RAPID COMMUN. MASS SPECTROM., vol. 10, pages 1019 - 1026
ROUSE ET AL., CELL, vol. 78, 1994, pages 1027
See also references of EP3052096A4
SIVARAMAN ET AL., J CLIN. INVEST., vol. 99, 1997, pages 1478
TSURUO, T ET AL.: "Platelet aggregation in the formation of tumor metastasis.", PROCEEDINGS OF THE JAPAN ACADEMY, SERIES B, vol. 84, no. 6, 2008, pages 189 - 198, XP055331728, Retrieved from the Internet <URL:https://www.jstage.jst.go.jp/artide/pjab/84/6/84_6_189/_pdf> [retrieved on 20141126] *
WHELCHEL ET AL., AM. J. RESPIR. CELL MOL. BIOL., vol. 16, 1997, pages 589

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10301317B2 (en) 2013-10-03 2019-05-28 Kura Oncology, Inc. Inhibitors of ERK and methods of use
WO2017222958A1 (en) * 2016-06-20 2017-12-28 Kura Oncology, Inc. Treatment of squamous cell carcinomas with inhibitors of erk
JP2019518063A (ja) * 2016-06-20 2019-06-27 クラ オンコロジー， インコーポレイテッド Ｅｒｋ阻害剤を用いた扁平上皮細胞癌の処置
WO2018177781A1 (en) 2017-03-28 2018-10-04 Basf Se Pesticidal compounds
WO2019076336A1 (zh) * 2017-10-19 2019-04-25 江苏豪森药业集团有限公司 含吡唑基的三并环类衍生物、其制备方法和应用
EP3643705A1 (en) 2018-10-24 2020-04-29 Basf Se Pesticidal compounds
WO2020083733A1 (en) 2018-10-24 2020-04-30 Basf Se Pesticidal compounds
CN113423707A (zh) * 2018-11-16 2021-09-21 加利福尼亚技术学院 Erk抑制剂及其用途
US12428416B2 (en) 2018-11-16 2025-09-30 California Institute Of Technology ERK inhibitors and uses thereof
EP3880677A4 (en) * 2018-11-16 2022-06-22 California Institute of Technology Erk inhibitors and uses thereof
WO2020102686A1 (en) * 2018-11-16 2020-05-22 California Institute Of Technology Erk inhibitors and uses thereof
WO2020200161A1 (zh) * 2019-04-02 2020-10-08 上海翰森生物医药科技有限公司 含吲唑基的三并环类衍生物的盐及其晶型
CN112020357A (zh) * 2019-04-02 2020-12-01 上海翰森生物医药科技有限公司 含吲唑基的三并环类衍生物的盐及其晶型
CN112020357B (zh) * 2019-04-02 2023-08-29 上海翰森生物医药科技有限公司 含吲唑基的三并环类衍生物的盐及其晶型
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
WO2021013561A1 (en) 2019-07-19 2021-01-28 Basf Se Pesticidal pyrazole and triazole derivatives
EP4198023A1 (en) 2021-12-16 2023-06-21 Basf Se Pesticidally active thiosemicarbazone compounds
WO2023110932A1 (en) 2021-12-16 2023-06-22 Basf Se Pesticidally active thiosemicarbazone compounds
WO2023156402A1 (en) 2022-02-17 2023-08-24 Basf Se Pesticidally active thiosemicarbazone compounds
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024240859A1 (en) 2023-05-25 2024-11-28 Basf Se Lactam pesticidal compounds
EP4467535A1 (en) 2023-05-25 2024-11-27 Basf Se Lactam pesticidal compounds
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025067459A2 (en) 2023-09-29 2025-04-03 D3 Bio (Wuxi) Co., Ltd. Therapies for the treatment of cancer
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Also Published As

Publication number Publication date
ME02991B (me) 2018-10-20
JP2019031549A (ja) 2019-02-28
EP3363800A1 (en) 2018-08-22
EA201690708A1 (ru) 2016-12-30
IL244488A0 (en) 2016-04-21
EP3052096A4 (en) 2017-03-15
PL3052096T3 (pl) 2018-07-31
SG11201602572YA (en) 2016-04-28
CA2924584A1 (en) 2015-04-09
JP2016531952A (ja) 2016-10-13
CN105636586B (zh) 2018-05-29
MX2016004163A (es) 2016-09-07
ZA201601701B (en) 2019-09-25
AU2018250439A1 (en) 2018-11-15
BR112016006994A8 (pt) 2020-02-27
SMT201800205T1 (it) 2018-05-02
US20170226110A1 (en) 2017-08-10
EP3052096B1 (en) 2018-01-17
EP3052096B8 (en) 2018-03-07
US9624228B2 (en) 2017-04-18
HK1255851A1 (en) 2019-08-30
AU2014331628A1 (en) 2016-03-24
US9951078B2 (en) 2018-04-24
PH12016500432B1 (en) 2016-05-16
EP3052096A1 (en) 2016-08-10
SI3052096T1 (en) 2018-04-30
AU2014331628B2 (en) 2018-08-30
DK3052096T3 (en) 2018-03-12
PT3052096T (pt) 2018-04-04
CY1120095T1 (el) 2018-12-12
EA032196B1 (ru) 2019-04-30
KR20160081908A (ko) 2016-07-08
ES2664794T3 (es) 2018-04-23
CN108864102A (zh) 2018-11-23
BR112016006994A2 (pt) 2017-08-01
LT3052096T (lt) 2018-04-10
JP6427197B2 (ja) 2018-11-21
CN105636586A (zh) 2016-06-01
HRP20180538T1 (hr) 2018-05-04
US10301317B2 (en) 2019-05-28
HUE036600T2 (hu) 2018-07-30
US20190292194A1 (en) 2019-09-26
US20180237444A1 (en) 2018-08-23
RS57058B1 (sr) 2018-05-31
PH12016500432A1 (en) 2016-05-16
US20160237091A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
DK3052096T3 (en) INHIBITORS OF ERK AND METHODS OF USE
CN102124009B (zh) 激酶抑制剂及其使用方法
CA2760791C (en) Heterocyclic compounds and uses thereof
JP5868596B2 (ja) 特定の化学的実体、組成物および方法
JP5731978B2 (ja) 複素環キナーゼ阻害剤
ES2900184T3 (es) Combinaciones terapéuticas de un inhibidor de BTK y un inhibidor de BCL-2
EP2252293B1 (en) Kinase inhibitors and methods of use
HK1227283B (en) Inhibitors of erk and methods of use
HK1227283A1 (en) Inhibitors of erk and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850964

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 244488

Country of ref document: IL

REEP Request for entry into the european phase

Ref document number: 2014850964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014850964

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2924584

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2014331628

Country of ref document: AU

Date of ref document: 20141003

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15026581

Country of ref document: US

Ref document number: MX/A/2016/004163

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2016546894

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016006994

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20167011270

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201690708

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112016006994

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160330